Olfactory ensheathing cells , olfactory nerve fibroblasts and biomatrices to promote long-distance axon regrowth and functional recovery in the dorsally hemisected adult rat spinal cord R. Deumens a , , G.C. Koopmans a , b , W.M.M. Honig b , F.P.T. Hamers c , V. Maquet d , R. Jérôme d , H.W.M. Steinbusch a , E.A.J. Joosten b a Department of Psychiatry and Neuropsychology , Division Neuroscience , European Graduate School of Neuroscience -LRB- EURON -RRB- , University of Maastricht , P.O. Box 616 , 6200 MD , Maastricht , The Netherlands b Department of Anesthesiology , Academic Hospital Maastricht , P.O. Box 5800 , 6202 AZ , Maastricht , The Netherlands c Department of Physical Medicine and Rehabilitation , Rudolf Magnus Institute for Neuroscience , University Medical Center Utrecht , Utrecht , The Netherlands d Center for Education and Research on Macromolecules , University of Liège , Sart-Tilman B6 , 4000 Liège , Belgium Abstract Cellular transplantation , including olfactory ensheathing cells -LRB- OEC -RRB- and olfactory nerve fibroblasts -LRB- ONF -RRB- , after experimental spinal cord injury in the rat	1
Olfactory ensheathing cells	1
olfactory nerve fibroblasts and biomatrices to promote long-distance axon regrowth and functional recovery in the dorsally hemisected adult rat spinal cord R. Deumens a , , G.C. Koopmans a , b , W.M.M. Honig b , F.P.T. Hamers c , V. Maquet d , R. Jérôme d , H.W.M. Steinbusch a , E.A.J. Joosten b a Department of Psychiatry and Neuropsychology , Division Neuroscience , European Graduate School of Neuroscience -LRB- EURON -RRB- , University of Maastricht , P.O. Box 616 , 6200 MD , Maastricht , The Netherlands b Department of Anesthesiology , Academic Hospital Maastricht , P.O. Box 5800 , 6202 AZ , Maastricht , The Netherlands c Department of Physical Medicine and Rehabilitation , Rudolf Magnus Institute for Neuroscience , University Medical Center Utrecht , Utrecht , The Netherlands d Center for Education and Research on Macromolecules , University of Liège , Sart-Tilman B6 , 4000 Liège , Belgium Abstract Cellular transplantation , including olfactory ensheathing cells -LRB- OEC -RRB-	30
olfactory nerve fibroblasts and biomatrices	30
long-distance axon regrowth and functional recovery in the dorsally hemisected adult rat spinal cord R. Deumens a , , G.C. Koopmans a , b , W.M.M. Honig b , F.P.T. Hamers c , V. Maquet d , R. Jérôme d , H.W.M. Steinbusch a , E.A.J. Joosten b a Department of Psychiatry and Neuropsychology , Division Neuroscience , European Graduate School of Neuroscience -LRB- EURON -RRB- , University of Maastricht , P.O. Box 616 , 6200 MD , Maastricht , The Netherlands b Department of Anesthesiology , Academic Hospital Maastricht , P.O. Box 5800 , 6202 AZ , Maastricht , The Netherlands c Department of Physical Medicine and Rehabilitation , Rudolf Magnus Institute for Neuroscience , University Medical Center Utrecht , Utrecht , The Netherlands d Center for Education and Research on Macromolecules , University of Liège , Sart-Tilman B6 , 4000 Liège , Belgium Abstract Cellular transplantation ,	85
long-distance axon regrowth and functional recovery	85
the dorsally hemisected adult rat	140
spinal cord R. Deumens a ,	174
spinal cord	174
R. Deumens a ,	186
R. Deumens	186
a	197
G.C. Koopmans a	202
G.C. Koopmans	202
a	216
b	218
W.M.M. Honig b	221
W.M.M. Honig	221
b	234
F.P.T. Hamers c	237
V. Maquet d	254
V. Maquet	254
d	264
R. Jérôme d	267
H.W.M. Steinbusch a	280
H.W.M. Steinbusch	280
a	298
E.A.J. Joosten b a Department of Psychiatry and Neuropsychology	301
E.A.J. Joosten	301
a Department	318
Psychiatry and Neuropsychology	334
Division Neuroscience	366
European Graduate School of Neuroscience -LRB- EURON -RRB-	389
European Graduate School	389
Neuroscience -LRB- EURON -RRB-	417
Neuroscience	417
EURON	431
University of Maastricht	439
University	439
Maastricht	453
P.O. Box 616 , 6200 MD	465
P.O. Box 616 , 6200	465
MD	484
Maastricht	488
The Netherlands b Department of Anesthesiology	500
The Netherlands b Department	500
Anesthesiology	532
Academic Hospital Maastricht	548
P.O. Box 5800 , 6202 AZ	578
P.O. Box 5800 , 6202	578
AZ	598
Maastricht	602
The Netherlands c Department of Physical Medicine and Rehabilitation	614
The Netherlands c Department	614
Physical Medicine and Rehabilitation	646
Rudolf Magnus Institute for Neuroscience	684
Rudolf Magnus Institute	684
Neuroscience	712
University Medical Center Utrecht	726
Utrecht	761
The Netherlands d Center for Education and Research on Macromolecules	770
The Netherlands d Center	770
Education and Research	799
Macromolecules	825
University of Liège	841
University	841
Liège	855
Sart-Tilman B6	862
4000 Liège	878
Belgium Abstract Cellular transplantation	890
Belgium Abstract Cellular	890
transplantation	918
olfactory ensheathing cells	945
OEC	974
olfactory nerve fibroblasts -LRB- ONF -RRB- , after experimental spinal cord injury in the rat	983
olfactory nerve fibroblasts	983
ONF	1012
experimental spinal cord injury in the rat	1024
experimental spinal cord injury	1024
the rat	1059
regrowth of severed corticospinal -LRB- CS -RRB-	1094
regrowth	1094
severed corticospinal -LRB- CS -RRB-	1106
severed corticospinal	1106
CS	1129
axons across small lesion gaps and partial functional recovery	1133
axons	1133
small lesion gaps and partial functional recovery	1146
small lesion gaps	1146
partial functional recovery	1168
CS axon regrowth	1219
large lesion gaps	1243
we	1262
a multifactorial transplantation strategy	1270
an OEC/ONF continuum in spinal cords	1322
an OEC/ONF continuum	1322
spinal cords	1346
a 2-mm-long dorsal hemisection lesion gap	1364
This strategy	1407
the use of aligned OEC/ONF -- poly -LRB- D , L -RRB- - lactide biomatrix bridges within the lesion gap and OEC/ONF injections at 1 mm rostral and caudal	1430
the use of aligned OEC/ONF	1430
the use	1430
aligned OEC/ONF	1441
poly -LRB- D , L -RRB-	1457
poly	1457
lactide biomatrix bridges within the lesion gap	1467
lactide biomatrix bridges	1467
the lesion gap	1500
OEC/ONF injections at 1 mm rostral and caudal	1519
OEC/ONF injections	1519
1 mm rostral and caudal	1541
1 mm rostral	1541
caudal	1558
the lesion gap	1568
the effects of this complete strategy	1601
the effects	1601
this complete strategy	1616
control animals	1640
injections	1670
culture medium rostral and caudal	1686
culture medium rostral	1686
caudal	1713
the lesion gap	1723
our multifactorial intervention	1753
an enhanced presence of injured CS axons directly rostral to the lesion gap -LRB- 65.0 ± 12.8 % in transplanted animals versus 13.1 ± 3.9 % in control animals -RRB-	1797
an enhanced presence	1797
injured CS axons directly rostral to the lesion gap -LRB- 65.0 ± 12.8 % in transplanted animals versus 13.1 ± 3.9 % in control animals -RRB-	1821
injured CS axons	1821
the lesion gap	1858
65.0 ± 12.8 % in transplanted animals versus 13.1 ± 3.9 % in control animals	1874
65.0 ± 12.8 % in	1874
65.0	1874
12.8 %	1881
transplanted animals versus 13.1	1890
transplanted animals	1890
13.1	1918
3.9 %	1925
control animals	1933
No regrowth of these axons	1951
No regrowth	1951
these axons	1966
the lesion site , which may be related to a lack of OEC/ONF survival on the biomatrices	1999
the lesion site	1999
a lack of OEC/ONF survival	2040
a lack	2040
OEC/ONF survival	2050
the biomatrices	2070
a 10-fold increase of neurofilament-positive axon ingrowth into the lesion site as compared to untreated control animals	2100
a 10-fold increase	2100
neurofilament-positive axon ingrowth into the lesion site as compared to untreated control animals	2122
neurofilament-positive axon ingrowth	2122
the lesion site as compared to untreated control animals	2164
the lesion site	2164
untreated control animals	2195
the use of quantitative gait analysis	2240
the use	2240
quantitative gait analysis	2251
a modest recovery in stride length and swing speed of the hind limbs	2279
a modest recovery	2279
stride length	2300
speed of the hind limbs	2324
speed	2324
the hind limbs	2333
multifactorial strategies	2371
repair of large spinal lesion gaps	2424
repair	2424
large spinal lesion gaps	2434
we	2460
the combined use of OEC/ONF and poly -LRB- D , L -RRB- - lactide biomatrices	2477
the combined use	2477
OEC/ONF and poly -LRB- D , L -RRB- - lactide biomatrices	2497
OEC/ONF and poly	2497
lactide biomatrices	2519
Introduction Axonal disruption	2560
the key factor	2594
respect to functional loss	2614
respect	2614
functional loss	2625
spinal cord injury -LRB- SCI -RRB-	2647
spinal cord injury	2647
SCI	2667
Spontaneous regeneration of severed axons	2673
Spontaneous regeneration	2673
severed axons	2701
the injuryinduced disbalance between growth-promoting and growthinhibiting factors	2749
the injuryinduced disbalance	2749
growth-promoting and growthinhibiting factors	2786
the spinal cord environment -LRB- Fawcett , 1997 -RRB-	2835
the spinal cord environment	2835
Fawcett	2864
1997	2873
Transplantation of growth-promoting grafts	2880
Transplantation	2880
growth-promoting grafts	2899
this balance	2975
experimental conditions	2994
axon regrowth and functional recovery -LRB- Deumens et al. , 2005 -RRB-	3040
axon regrowth and functional recovery	3040
axon regrowth	3040
Deumens	3079
et al. , 2005	3087
et al.	3087
2005	3095
the last decade	3105
mixed cultures of olfactory ensheathing cells -LRB- OEC -RRB- and olfactory nerve fibroblasts -LRB- ONF -RRB- and purified OEC cultures	3122
mixed cultures of olfactory ensheathing cells -LRB- OEC -RRB- and olfactory nerve fibroblasts -LRB- ONF -RRB-	3122
mixed cultures	3122
olfactory ensheathing cells -LRB- OEC -RRB- and olfactory nerve fibroblasts -LRB- ONF -RRB-	3140
olfactory ensheathing cells	3140
OEC	3169
olfactory nerve fibroblasts	3178
ONF	3207
purified OEC cultures	3216
a possible therapeutic tool in experimental SCI research -LRB- Raisman , 2001 -RRB-	3270
a possible therapeutic tool	3270
experimental SCI research -LRB- Raisman , 2001 -RRB-	3301
experimental SCI research	3301
Raisman , 2001	3328
Raisman	3328
2001	3337
OEC	3361
the mammalian olfactory system , where they stimulate olfactory axon regeneration throughout the lifespan of the organism -LRB- Ramon-Cueto and Avila , 1998 -RRB- , a process which is thought to be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3375
the mammalian olfactory system	3375
they	3413
olfactory axon regeneration	3428
the lifespan of the organism -LRB- Ramon-Cueto and Avila , 1998 -RRB- , a process which is thought to be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3467
the lifespan	3467
the organism -LRB- Ramon-Cueto and Avila , 1998 -RRB- , a process which is thought to be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3483
the organism -LRB- Ramon-Cueto and Avila , 1998 -RRB-	3483
the organism	3483
Ramon-Cueto and Avila , 1998	3497
Ramon-Cueto	3497
Avila , 1998	3513
Avila	3513
1998	3520
a process which is thought to be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3527
a process	3527
the presence of ONF -LRB- Raisman , 2001 -RRB-	3585
the presence	3585
ONF -LRB- Raisman , 2001 -RRB-	3601
ONF	3601
Raisman , 2001	3606
Raisman	3606
2001	3615
incomplete/complete rat spinal lesion sites	3653
mixed OEC/ONF or purified OEC	3698
mixed OEC/ONF	3698
purified OEC	3715
-LSB- 1 -RSB- regrowth of axons from various injured tracts , such as the corticospinal -LRB- CS -RRB- -LRB- Li et al. , 1997 , 1998 -RRB- , raphespinal -LRB- Lu et al. , 2001 -RRB- , reticulospinal -LRB- Plant et al. , 2003 -RRB- , and coerulospinal tract -LRB- Ramon-Cueto et al. , 2000 -RRB- , -LSB- 2 -RSB- restoration in the signal conduction across the lesion / graft site -LRB- Imaizumi et al. , 2000 -RRB- , and -LSB- 3 -RSB- recovery of body functions , such as locomotor functions -LRB- Li et al. , 1998 -RRB- , respiratory functions -LRB- Li et al. , 2003 -RRB- , and sensory functions -LRB- Ramon-Cueto et al. , 2000 -RRB-	3744
-LSB- 1 -RSB- regrowth	3744
axons from various injured tracts	3760
axons	3760
various injured tracts	3771
the corticospinal -LRB- CS -RRB- -LRB- Li et al. , 1997 , 1998 -RRB- , raphespinal -LRB- Lu et al. , 2001 -RRB- , reticulospinal -LRB- Plant et al. , 2003 -RRB- , and coerulospinal tract -LRB- Ramon-Cueto et al. , 2000 -RRB- , -LSB- 2 -RSB- restoration in the signal conduction across the lesion / graft site -LRB- Imaizumi et al. , 2000 -RRB- , and -LSB- 3 -RSB- recovery of body functions , such as locomotor functions -LRB- Li et al. , 1998 -RRB- , respiratory functions -LRB- Li et al. , 2003 -RRB- , and sensory functions -LRB- Ramon-Cueto et al. , 2000 -RRB-	3803
the corticospinal -LRB- CS -RRB- -LRB- Li et al. , 1997 , 1998 -RRB- , raphespinal -LRB- Lu et al. , 2001 -RRB- , reticulospinal -LRB- Plant et al. , 2003 -RRB- , and coerulospinal tract -LRB- Ramon-Cueto et al. , 2000 -RRB-	3803
the corticospinal -LRB- CS -RRB- -LRB- Li et al. , 1997 , 1998 -RRB-	3803
the corticospinal -LRB- CS -RRB-	3803
the corticospinal	3803
Li	3827
et al. , 1997 , 1998	3830
et al.	3830
1997	3838
1998	3844
raphespinal -LRB- Lu et al. , 2001 -RRB-	3851
raphespinal	3851
Lu	3864
et al. , 2001	3867
et al.	3867
2001	3875
reticulospinal -LRB- Plant et al. , 2003 -RRB-	3882
reticulospinal	3882
Plant	3898
et al. , 2003	3904
et al.	3904
2003	3912
coerulospinal tract -LRB- Ramon-Cueto et al. , 2000 -RRB-	3923
coerulospinal tract	3923
Ramon-Cueto	3944
et al. , 2000	3956
et al.	3956
2000	3964
-LSB- 2 -RSB- restoration in the signal conduction across the lesion / graft site -LRB- Imaizumi et al. , 2000 -RRB-	3971
-LSB- 2 -RSB- restoration	3971
the signal conduction across the lesion / graft site -LRB- Imaizumi et al. , 2000 -RRB-	3990
the signal conduction	3990
the lesion / graft site -LRB- Imaizumi et al. , 2000 -RRB-	4019
the lesion / graft site	4019
the lesion	4019
graft site	4031
Imaizumi	4043
et al. , 2000	4052
et al.	4052
2000	4060
3 -RSB- recovery of body functions	4072
-RSB- recovery	4073
body functions	4087
locomotor functions -LRB- Li et al. , 1998 -RRB- , respiratory functions -LRB- Li et al. , 2003 -RRB- , and sensory functions -LRB- Ramon-Cueto et al. , 2000 -RRB-	4111
locomotor functions -LRB- Li et al. , 1998 -RRB-	4111
locomotor functions	4111
Li	4132
et al. , 1998	4135
et al.	4135
1998	4143
respiratory functions -LRB- Li et al. , 2003 -RRB-	4150
respiratory functions	4150
Li	4173
et al. , 2003	4176
et al.	4176
2003	4184
sensory functions -LRB- Ramon-Cueto et al. , 2000 -RRB-	4195
sensory functions	4195
Ramon-Cueto	4214
et al. , 2000	4226
et al.	4226
2000	4234
The CST	4241
a low regenerative response	4266
injury -LRB- Joosten , 1997 -RRB-	4300
injury	4300
Joosten	4308
1997	4317
regrowth of injured CS axons	4333
regrowth	4333
injured CS axons	4345
transplantation of mixed OEC/ONF	4388
transplantation	4388
mixed OEC/ONF	4407
OEC cultures	4434
the injured spinal cord tissue	4452
the spinal cord injury models	4484
small spinal lesion gaps	4531
the injured human spinal cord	4560
large cystic cavities	4591
long-distance axon regrowth	4636
Long-distance axon regeneration of olfactory axons	4665
Long-distance axon regeneration	4665
olfactory axons	4700
both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4749
OEC	4754
ONF -LRB- Li et al. , 2005 -RRB-	4762
ONF	4762
Li	4767
et al. , 2005	4770
et al.	4770
2005	4778
we	4796
transplanted OEC/ONF cultures	4817
repair of injured CS axons across large spinal lesion gaps	4855
repair	4855
injured CS axons across large spinal lesion gaps	4865
injured CS axons	4865
large spinal lesion gaps	4889
regrowth of injured CS axons across large lesion gaps	4924
regrowth	4924
injured CS axons across large lesion gaps	4936
injured CS axons	4936
large lesion gaps	4960
a growth-stimulating source , such as OEC / ONF , but also a physical substrate to bridge the lesion gap	4999
a growth-stimulating source , such as OEC / ONF	4999
a growth-stimulating source	4999
OEC / ONF	5036
OEC	5036
ONF	5041
a physical substrate to bridge the lesion gap	5055
the lesion gap	5086
the use of millions of autologous growthpromoting cells	5120
the use	5120
millions of autologous growthpromoting cells	5131
millions	5131
autologous growthpromoting cells	5143
other bridges	5177
growth-promoting tissues -LRB- Coumans et al. , 2001 -RRB- , growthpromoting cells secreting extracellular matrix molecules -LRB- Li et al. , 2003 -RRB- , and organic bridges -LRB- Schnell and Schwab , 1993 -RRB-	5220
growth-promoting tissues -LRB- Coumans et al. , 2001 -RRB-	5220
growth-promoting tissues	5220
Coumans	5246
et al. , 2001	5254
et al.	5254
2001	5262
growthpromoting cells secreting extracellular matrix molecules -LRB- Li et al. , 2003 -RRB- , and organic bridges -LRB- Schnell and Schwab , 1993 -RRB-	5269
growthpromoting cells	5269
extracellular matrix molecules -LRB- Li et al. , 2003 -RRB- , and organic bridges -LRB- Schnell and Schwab , 1993 -RRB-	5301
extracellular matrix molecules -LRB- Li et al. , 2003 -RRB-	5301
extracellular matrix molecules	5301
Li	5333
et al. , 2003	5336
et al.	5336
2003	5344
organic bridges -LRB- Schnell and Schwab , 1993 -RRB-	5355
organic bridges	5355
Schnell and Schwab	5372
1993	5392
the present study	5402
a multifactorial transplantation strategy including a physical bridge	5421
a multifactorial transplantation strategy	5421
a physical bridge	5473
an OEC/ONF continuum in rat spinal cords	5510
an OEC/ONF continuum	5510
rat spinal cords	5534
large lesion gaps	5556
dorsal hemisection	5581
CS axon regrowth -LRB- Schnell and Schwab , 1990 ; Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al. , 2002 -RRB-	5623
CS axon regrowth	5623
Schnell and Schwab , 1990 ; Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al. , 2002	5641
Schnell and Schwab	5641
1990 ; Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5661
1990	5661
Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5667
Schnell	5667
et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5675
et al. , 1994	5675
et al.	5675
1994	5683
Grill et al. , 1997	5689
Grill	5689
et al. , 1997	5695
et al.	5695
1997	5703
GrandPre et al.	5709
GrandPre	5709
et al.	5718
2002	5726
we	5733
a 2-mm-long dorsal hemisection lesion	5741
OEC/ONF -- biomatrix complexes , which have been shown to stimulate directional neurite growth in vitro -LRB- Deumens et al. , 2004 -RRB-	5788
OEC/ONF -- biomatrix complexes , which have been shown to stimulate directional neurite growth in vitro	5788
OEC/ONF	5788
biomatrix complexes , which have been shown to stimulate directional neurite growth in vitro	5796
biomatrix complexes	5796
directional neurite growth	5852
Deumens	5889
et al. , 2004	5897
et al.	5897
2004	5905
the 2-mmlong dorsal hemisection	5943
lesion gaps	5975
addition	5991
OEC/ONF suspensions	6001
the thoracic lesion site	6057
Migration of OEC/ONF after transplantation into the injured spinal cord , as has been previously reported -LRB- Li et al. , 1997 , 1998 -RRB-	6083
Migration	6083
OEC/ONF after transplantation into the injured spinal cord , as has been previously reported -LRB- Li et al. , 1997 , 1998 -RRB-	6096
OEC/ONF	6096
transplantation into the injured spinal cord , as has been previously reported -LRB- Li et al. , 1997 , 1998 -RRB-	6110
transplantation	6110
the injured spinal cord , as has been previously reported	6131
the injured spinal cord	6131
Li	6189
et al. , 1997 , 1998	6192
et al.	6192
1997	6200
1998	6206
a continuum of OEC/ONF	6229
a continuum	6229
OEC/ONF	6244
the injured spinal cord	6255
the effect of this multifactorial treatment including OEC/ONF -- biomatrix complexes and OEC/ONF cell injections	6298
the effect	6298
this multifactorial treatment including OEC/ONF -- biomatrix complexes and OEC/ONF cell injections	6312
this multifactorial treatment	6312
OEC/ONF -- biomatrix complexes and OEC/ONF cell injections	6352
OEC/ONF	6352
biomatrix complexes and OEC/ONF cell injections	6360
biomatrix complexes	6360
OEC/ONF cell injections	6384
control animals	6409
a graft	6441
the lesion site	6456
culture medium injections rostral and caudal	6485
culture medium injections	6485
the injury site	6533
We	6550
our multifactorial transplantation strategy	6570
regrowth of injured CS axons across the large spinal lesion site and subsequently recovery of impaired body functions	6625
regrowth	6625
injured CS axons across the large spinal lesion site and subsequently recovery of impaired body functions	6637
injured CS axons across the large spinal lesion site	6637
injured CS axons	6637
the large spinal lesion site	6661
recovery of impaired body functions	6707
recovery	6707
impaired body functions	6719
Materials and methods	6745
Materials	6745
methods	6759
General All experimental procedures were performed according to the recommendations of the European Commission -LRB- European Communities Council Directive of 24 November 1986 ; 86/609 / EEC -RRB- , and protocols were approved by the Committee on Animal Research of the Maastricht University	6767
General All	6767
experimental procedures	6779
the recommendations of the European Commission -LRB- European Communities Council Directive of 24 November 1986 ; 86/609 / EEC -RRB-	6831
the recommendations	6831
the European Commission -LRB- European Communities Council Directive of 24 November 1986 ; 86/609 / EEC -RRB-	6854
the European Commission	6854
European Communities Council Directive of 24 November 1986 ; 86/609 / EEC	6879
European Communities Council Directive of 24 November 1986 ; 86/609 /	6879
European Communities Council Directive	6879
24 November 1986 ; 86/609 /	6921
24 November 1986	6921
86/609	6939
EEC	6947
protocols	6957
the Committee	6984
Animal Research of the Maastricht University	7001
Animal Research	7001
the Maastricht University	7020
DEC 2004-030	7047
this study	7065
every attempt	7077
the number of animals and their suffering	7112
the number	7112
animals and their suffering	7126
animals	7126
their suffering	7138
Male Lewis rats -LRB- inbred , animal facilities of Maastricht University -RRB- , 7 weeks old , 200 -- 250 g in body weight ,	7155
Male Lewis rats	7155
inbred , animal facilities of Maastricht University	7172
inbred , animal facilities	7172
Maastricht University	7201
7 weeks old	7225
7 weeks	7225
200 -- 250 g in body weight	7238
200	7238
250 g in body weight	7242
250 g	7242
body weight	7251
CatWalk behavioral testing -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	7284
CatWalk behavioral testing	7284
Hamers	7312
et al. , 2001 ; Koopmans et al. , 2005	7319
et al.	7319
2001 ; Koopmans et al.	7327
2001	7327
Koopmans et al.	7333
Koopmans	7333
et al.	7342
2005	7350
they	7362
three consecutive runs	7390
hesitation	7421
the age of 9 weeks	7436
the age	7436
9 weeks	7447
the animals	7456
the CatWalk	7496
preoperative CatWalk data	7518
a dorsal hemisection of the spinal cord	7551
a dorsal hemisection	7551
the spinal cord	7575
T11/T12	7608
animals	7621
two groups	7656
one group -LRB- n = 10 -RRB-	7668
one group	7668
n	7679
10	7683
OEC/ONF -- biomatrix transplants	7696
OEC/ONF	7696
biomatrix transplants	7704
the lesion site and OEC/ONF suspensions	7731
the lesion site	7731
OEC/ONF suspensions	7751
the rostral and caudal cord stumps	7776
the rostral	7776
caudal cord stumps	7792
the other group -LRB- n = 8 -RRB-	7816
the other group	7816
n	7833
8	7837
transplants	7856
the lesion site	7873
injections of culture medium	7903
injections	7903
culture medium	7917
the rostral and caudal host stumps	7937
the rostral	7937
caudal host stumps	7953
this	7979
the animals	7985
the Basso -- Beattie -- Bresnahan locomotor rating scale -LRB- Basso et al. , 1995 -RRB- and the CatWalk gait analysis for 9 weeks	8028
the Basso -- Beattie -- Bresnahan locomotor rating scale -LRB- Basso et al. , 1995 -RRB-	8028
the Basso -- Beattie -- Bresnahan locomotor rating scale	8028
Beattie	8038
Basso	8081
et al. , 1995	8087
et al.	8087
1995	8095
the CatWalk gait analysis for 9 weeks	8105
the CatWalk gait analysis	8105
9 weeks	8135
the CS tract	8162
an additional surgery	8176
6 weeks	8215
injury	8229
Nine weeks	8237
SCI	8254
the animals	8259
histological analysis	8305
the postoperative period	8339
histological analysis	8375
the researchers	8398
the treatment	8428
OEC/ONF cultures	8443
The isolation of mixed OEC/ONF cultures	8460
The isolation	8460
mixed OEC/ONF cultures	8477
syngeneic cells	8511
the outer two glomerular layers of adult rat	8532
the outer two glomerular layers	8532
adult rat	8567
olfactory bulbs	8577
that described previously -LRB- Li et al. , 1998 -RRB-	8610
that	8610
Li et al. , 1998	8637
Li	8637
et al.	8640
1998	8648
a method developed by Ramon-Cueto and co-workers -LRB- Ramon-Cueto and Nieto - Sampedro , 1992 -RRB-	8672
a method	8672
Ramon-Cueto and co-workers -LRB- Ramon-Cueto and Nieto - Sampedro , 1992 -RRB-	8694
Ramon-Cueto	8694
co-workers -LRB- Ramon-Cueto and Nieto - Sampedro , 1992 -RRB-	8710
co-workers	8710
Ramon-Cueto and Nieto - Sampedro , 1992	8722
Ramon-Cueto and Nieto	8722
Ramon-Cueto	8722
Nieto	8738
Sampedro , 1992	8745
Sampedro	8745
1992	8755
9-week-old Lewis rats -LRB- inbred ; animal facilities of Maastricht University -RRB-	8771
9-week-old Lewis rats	8771
inbred ; animal facilities of Maastricht University	8794
inbred	8794
animal facilities of Maastricht University	8802
animal facilities	8802
Maastricht University	8823
the olfactory bulbs	8868
meninges	8918
the outer olfactory nerve fiber and glomerular layers	8934
the outer olfactory nerve fiber	8934
glomerular layers	8970
The tissue	9014
small fragments	9038
trypsin -LRB- 0.1 % in phosphate-buffered saline ; Gibco/Invitrogen , Breda , The Netherlands -RRB-	9073
trypsin	9073
0.1 % in phosphate-buffered saline ; Gibco/Invitrogen , Breda , The Netherlands	9082
0.1 %	9082
phosphate-buffered saline ; Gibco/Invitrogen , Breda , The Netherlands	9090
phosphate-buffered saline	9090
Gibco/Invitrogen , Breda , The Netherlands	9117
Gibco/Invitrogen , Breda	9117
The Netherlands	9142
37 °C for 15 min	9162
37 °C	9162
15 min	9171
Trypsinization	9179
addition of culture medium	9209
addition	9209
culture medium	9221
Dulbecco 's Modified Eagle 's medium -LRB- DMEM/NUT mix F12 ; Gibco/Invitrogen , Breda , The Netherlands -RRB- with glutamax-I supplemented with 10 % inactivated fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB- and antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB- was the only culture medium	9237
Dulbecco 's	9237
Eagle 's medium -LRB- DMEM/NUT mix F12 ; Gibco/Invitrogen , Breda , The Netherlands -RRB-	9257
Eagle 's medium	9257
Eagle 's	9257
DMEM/NUT mix F12 ; Gibco/Invitrogen	9273
DMEM/NUT mix F12	9273
Gibco/Invitrogen	9291
Breda , The Netherlands	9309
Breda	9309
The Netherlands	9316
glutamax-I supplemented with 10 % inactivated fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB- and antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB- was the only culture	9338
glutamax-I	9338
10 % inactivated fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB- and antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB- was the only culture	9367
10 %	9367
fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB- and antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB-	9383
fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB-	9383
fetal calf serum	9383
Bodinco	9401
Alkmaar	9410
The Netherlands	9419
antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB-	9440
antibiotics	9440
100 U/ml penicillin and 100 μg/ml streptomycin	9453
100 U/ml penicillin	9453
100 μg/ml streptomycin	9477
the only culture	9505
this study	9537
The tissue	9549
culture medium	9582
1 ml culture medium	9614
single cell dissociation	9641
mechanical trituration	9682
The cells	9706
PLL-coated Petri dishes	9731
a density of 200,000 cells in 2 ml of culture medium per Petri dish	9758
a density	9758
200,000 cells in 2 ml of culture medium per Petri dish	9771
200,000 cells	9771
2 ml of culture medium per Petri dish	9788
2 ml	9788
culture medium per Petri dish	9796
culture medium	9796
Petri dish	9815
The cells	9827
4	9852
5 days before half of the culture medium	9854
5 days	9854
half of the culture medium	9868
half	9868
the culture medium	9876
the culture medium	9922
every 2 days	9955
It	9969
this protocol	9986
mixed cultures containing both OEC and ONF -LRB- Li et al. , 1997 ; Deumens et al. , 2004 -RRB-	10008
mixed cultures	10008
OEC and ONF	10039
Li	10052
et al. , 1997 ; Deumens et al. , 2004	10055
et al.	10055
1997 ; Deumens et al.	10063
1997	10063
Deumens et al.	10069
Deumens	10069
et al.	10077
2004	10085
these cultures	10103
OEC/ONF cultures	10132
Poly -LRB- D , L -RRB- - lactide matrices Poly -LRB- D , L -RRB- - lactide with inherent viscosity of 1.62 dl/g was purchased from Purac Biochem -LRB- Gorinchem , The Netherlands -RRB- .	10150
Poly	10150
lactide matrices Poly -LRB- D , L -RRB- - lactide with inherent viscosity of 1.62 dl/g was purchased from Purac Biochem -LRB- Gorinchem , The Netherlands -RRB-	10160
lactide matrices Poly -LRB- D , L -RRB-	10160
lactide matrices	10160
Poly -LRB- D , L -RRB-	10177
Poly	10177
lactide with inherent viscosity of 1.62 dl/g	10187
lactide	10187
inherent viscosity of 1.62 dl/g	10200
inherent viscosity	10200
1.62 dl/g	10222
Purac Biochem -LRB- Gorinchem , The Netherlands -RRB-	10251
Purac Biochem	10251
Gorinchem	10266
The Netherlands	10277
A diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB- -LRB- PLA-b-PEO -RRB- copolymer with a PLA block of approximately 4000 of molecular weight	10295
A diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB- -LRB- PLA-b-PEO -RRB- copolymer	10295
diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB- -LRB- PLA-b-PEO -RRB-	10297
diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB-	10297
diblock poly	10297
D,L-lactide-b-polyethylene oxide	10310
PLA-b-PEO	10345
a PLA block of approximately 4000 of molecular weight	10371
a PLA block	10371
approximately 4000 of molecular weight	10386
approximately 4000	10386
molecular weight	10408
ring-opening polymerization of D,L-lactide	10444
ring-opening polymerization	10444
D,L-lactide	10475
PEO-monomethyl-ether -LRB- with molecular weight	10492
PEO-monomethyl-ether	10492
molecular weight	10519
approximately 5000 , supplied by Sigma ,	10540
approximately 5000	10540
Sigma	10572
Uithoorn , The Netherlands	10579
Uithoorn	10579
The Netherlands	10589
Polymer foams	10607
a mixture of PLA	10640
a mixture	10640
PLA	10653
10	10668
% of PLA-b-PEO amphiphilic copolymer -LRB- PLA/PLA-b-PEO -RRB- .	10674
%	10674
PLA-b-PEO amphiphilic copolymer -LRB- PLA/PLA-b-PEO -RRB-	10679
PLA-b-PEO amphiphilic copolymer	10679
PLA/PLA-b-PEO	10712
Polymer foams with an aligned pore structure	10728
Polymer foams	10728
an aligned pore structure	10747
freeze-drying of polymer solutions , as previously described -LRB- Maquet et al. , 2001 -RRB-	10790
freeze-drying	10790
polymer solutions , as previously described	10807
polymer solutions	10807
Maquet	10851
et al. , 2001	10858
et al.	10858
2001	10866
The polymer	10873
dimethylcarbonate	10902
a 5	10929
% polymer solution .	10936
%	10936
polymer solution	10938
The solution	10956
immersion	10991
liquid nitrogen	11006
solvent crystallization	11041
the frozen system	11072
a vacuum pump	11107
the solvent	11126
sublimation at − 10 °C and 10 − 2 Torr	11153
sublimation at − 10 °C	11153
sublimation	11153
− 10 °C	11168
10 − 2 Torr	11178
10 −	11178
2 Torr	11181
48 h	11195
the drying temperature	11201
0 °C	11241
the drying process	11249
The foams	11283
room temperature	11315
Small polymer rods -LRB- 1 × 1 × 10 mm -RRB-	11333
Small polymer rods	11333
1 × 1 × 10 mm	11353
1 ×	11353
1 × 10 mm	11357
1 ×	11357
10 mm	11361
the freeze-dried foams using a razor blade	11382
the freeze-dried foams	11382
a razor blade	11411
UV exposure for 15 min	11443
UV exposure	11443
15 min	11459
OEC/ONF on poly -LRB- D , L -RRB- - lactide matrices OEC/ONF cultures that were grown in vitro for 10 days -LRB- Days in vitro 10 ; DIV10 -RRB- were collected from the Petri dishes by a 5-min incubation in 0.1 % trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution at 37 °C .	11467
OEC/ONF on poly -LRB- D , L -RRB-	11467
OEC/ONF	11467
poly -LRB- D , L -RRB-	11478
poly	11478
lactide matrices OEC/ONF cultures that were grown in vitro for 10 days -LRB- Days in vitro 10 ; DIV10 -RRB- were collected from the Petri dishes by a 5-min incubation in 0.1 % trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution at 37 °C	11488
lactide matrices	11488
OEC/ONF cultures that were grown in vitro for 10 days -LRB- Days in vitro 10 ; DIV10 -RRB-	11505
OEC/ONF cultures	11505
10 days -LRB- Days in vitro 10 ; DIV10 -RRB-	11551
10 days	11551
Days in vitro 10 ; DIV10	11560
Days	11560
vitro 10 ; DIV10	11568
vitro 10	11568
vitro	11568
10	11574
DIV10	11578
the Petri dishes	11605
a 5-min incubation in 0.1 % trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution at 37 °C	11625
a 5-min incubation	11625
0.1 % trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution at 37 °C	11647
0.1 %	11647
trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution at 37 °C	11652
trypsin/0 .05 mM EDTA -LRB- Fluka BioChemika , Buchs , Switzerland -RRB- solution	11652
Fluka BioChemika , Buchs , Switzerland	11674
Fluka BioChemika	11674
Buchs , Switzerland	11692
37 °C	11724
Trypsinization	11730
culture medium	11763
a 10-min centrifugation at 1200 rpm	11785
a 10-min centrifugation	11785
1200 rpm	11812
the pellet	11822
culture medium	11852
OEC/ONF cultures	11868
the surface area of the PLA/PLA-b-PEO matrices	11904
the surface area	11904
the PLA/PLA-b-PEO matrices	11924
a density of about 40,000 cells per cm2	11954
a density	11954
40,000 cells per cm2	11973
40,000 cells	11973
cm2	11990
these substrates for 4 days	12007
these substrates	12007
4 days	12028
This protocol	12036
aligned OEC/ONF -- biomatrix complexes as described previously -LRB- Deumens et al. , 2004 -RRB-	12058
aligned OEC/ONF	12058
biomatrix complexes as described previously -LRB- Deumens et al. , 2004 -RRB-	12074
biomatrix complexes	12074
Deumens	12119
et al. , 2004	12127
et al.	12127
2004	12135
Prelabeling of OEC/ONF before transplantation One day before transplantation , both the OEC/ONF cultures and the OEC/ONF -- biomatrix complexes	12142
Prelabeling	12142
OEC/ONF before transplantation One day before transplantation , both the OEC/ONF cultures and the OEC/ONF -- biomatrix complexes	12157
OEC/ONF	12157
transplantation	12172
One day	12188
transplantation	12203
both the OEC/ONF cultures and the OEC/ONF	12220
the OEC/ONF cultures	12225
the OEC/ONF	12250
biomatrix complexes	12262
Hoechst	12303
This	12312
a 40 - to 60-min incubation at 37 °C in 2 μg/ml Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB- in culture medium	12329
a 40	12329
60-min incubation at 37 °C in 2 μg/ml	12338
60-min incubation	12338
37 °C in 2 μg/ml	12359
37 °C	12359
2 μg/ml	12367
Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB- in culture medium	12375
Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB-	12375
Hoechst 33342	12375
Sigma	12390
Uithoorn	12397
The Netherlands	12407
culture medium	12427
the OEC/ONF cultures and OEC/ONF -- biomatrices	12455
the OEC/ONF cultures and OEC/ONF	12455
biomatrices	12488
culture medium	12529
Surgeries General	12545
every operation	12567
i.e. SCI , transplantation , and CS tract labeling	12584
i.e.	12584
SCI , transplantation , and CS tract labeling	12589
SCI	12589
transplantation	12594
CS tract labeling	12615
animals	12635
intraperitoneal -LRB- i.p. -RRB- injections	12652
Buprenorfine -LRB- Temgesic 0.1 ml/animal ; Schering-Plough , Utrecht , The Netherlands -RRB-	12691
Buprenorfine	12691
Temgesic 0.1 ml/animal	12705
Temgesic	12705
0.1 ml/animal	12714
Schering-Plough , Utrecht , The Netherlands	12729
Schering-Plough	12729
Utrecht	12746
The Netherlands	12755
One hour	12773
the injection	12788
the animals	12803
a mixture of 1	12838
a mixture	12838
1	12851
2 % halothane -LRB- Abbott , Hoofddorp , The Netherlands -RRB- and O2/N2O -LRB- 1:2 -RRB-	12853
2 % halothane -LRB- Abbott , Hoofddorp , The Netherlands -RRB-	12853
2 % halothane	12853
Abbott	12867
Hoofddorp	12875
The Netherlands	12886
O2/N2O -LRB- 1:2 -RRB-	12907
O2/N2O	12907
1:2	12915
an ophthalmic ointment , Visagel -LRB- Eurovet , Bladel , The Netherlands -RRB- ,	12924
an ophthalmic ointment	12924
Visagel -LRB- Eurovet , Bladel , The Netherlands -RRB-	12948
Visagel	12948
Eurovet	12957
Bladel	12966
The Netherlands	12974
the eyes	13007
the operation	13041
the beginning of every operation	13059
the beginning	13059
every operation	13076
the hair overlying the operation area	13093
the hair	13093
the operation area	13112
the skin	13146
Bethadine	13173
the end of every operation	13187
the end	13187
every operation	13198
the muscles and skin	13215
animals	13253
awake	13281
their home cages	13308
At least 1 h	13326
their awakening	13345
the animals	13362
another i.p. injection	13383
Buprenorfine	13411
SCI , transplantation Laminectomy	13425
SCI	13425
transplantation Laminectomy	13430
the spinal cord	13477
T11/T12	13508
The dura mater	13517
the use of microscissors	13549
the use	13549
microscissors	13560
the dorsal half of the spinal cord	13574
the dorsal half	13574
the spinal cord	13593
two spinal levels	13624
2 mm	13643
an aspiration device	13661
the dorsal part of the spinal cord in between the two cuts	13683
the dorsal part	13683
the spinal cord in between the two cuts	13702
the spinal cord	13702
the two cuts	13729
The depth of the lesion	13755
The depth	13755
the lesion	13768
1.2 mm	13783
care	13795
the dorsal part of the CS tract	13831
the dorsal part	13831
the CS tract	13850
the ventral-most part of the dorsal funiculus	13874
the ventral-most part	13874
the dorsal funiculus	13899
This lesion	13921
descending rubrospinal axons , the dorsal component of the CS tract , all ascending dorsal column axons , and local spinal sensory neurites	13944
descending rubrospinal axons	13944
the dorsal component of the CS tract	13974
the dorsal component	13974
the CS tract	13998
all ascending dorsal column axons	14012
all	14012
dorsal column axons	14026
local spinal sensory neurites	14051
The experimental group	14082
10 animals receiving an OEC/ONF -- biomatrix transplant into the thoracic lesion site which was then covered with DuraFilm	14118
10 animals	14118
an OEC/ONF -- biomatrix transplant	14139
an OEC/ONF	14139
biomatrix transplant	14150
the thoracic lesion site which was then covered with DuraFilm	14176
the thoracic lesion site	14176
DuraFilm	14229
addition	14242
OEC/ONF suspensions -LRB- 100,000 cells/μl ; 2 μl per injection site ; 1 injection site/stump -RRB-	14252
OEC/ONF suspensions	14252
100,000 cells/μl ; 2 μl per injection site ; 1 injection site/stump	14273
100,000 cells/μl	14273
2 μl per injection site ; 1 injection site/stump	14291
2 μl per injection site	14291
2 μl	14291
injection site	14300
1 injection site/stump	14316
the rostral and caudal cord stumps	14359
the rostral	14359
caudal cord stumps	14375
a distance of 1 mm	14397
a distance	14397
1 mm	14411
the lesion site	14421
a depth of 1.2 mm	14444
a depth	14444
1.2 mm	14455
The control group	14463
8 animals receiving injections of culture medium into the rostral and caudal cord stumps -LRB- 2 μl per injection site -RRB- at a distance of 1 mm from the lesion site and at a depth of 1.2 mm	14494
8 animals	14494
injections of culture medium	14514
injections	14514
culture medium	14528
the rostral and caudal cord stumps -LRB- 2 μl per injection site -RRB-	14548
the rostral	14548
caudal cord stumps -LRB- 2 μl per injection site -RRB-	14564
caudal cord stumps	14564
2 μl per injection site	14584
2 μl	14584
injection site	14593
a distance of 1 mm	14612
a distance	14612
1 mm	14626
the lesion site	14636
a depth of 1.2 mm	14659
a depth	14659
1.2 mm	14670
These culture injections	14678
possible damage induced by the injection procedure	14728
possible damage	14728
the injection procedure	14755
The control animals	14780
a transplant	14816
the lesion site	14834
CS tract labeling A dental drill	14851
CS tract labeling A	14851
dental drill	14871
burr holes	14901
both sides of the cranium overlying the sensorimotor cortices	14915
both sides	14915
the cranium overlying the sensorimotor cortices	14929
the cranium	14929
the sensorimotor cortices	14951
The anterograde neuronal tracer biotin dextran amine -LRB- BDA ; MW 10,000 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	14978
The anterograde neuronal tracer biotin dextran amine	14978
BDA ; MW 10,000 ; Molecular Probes/Invitrogen	15032
BDA	15032
MW 10,000 ; Molecular Probes/Invitrogen	15037
MW 10,000	15037
Molecular Probes/Invitrogen	15048
Breda , The Netherlands	15077
Breda	15077
The Netherlands	15084
the sensorimotor cortex	15126
a depth of 2 mm	15153
a depth	15153
2 mm	15164
the cortical surface on both sides -LRB- 10 % in 0.1 M phosphate-buffered saline -LRB- PBS -RRB- , pH 7.2 ; 1.5 μl/3 injections / hemisphere -RRB-	15174
the cortical surface	15174
both sides -LRB- 10 % in 0.1 M phosphate-buffered saline -LRB- PBS -RRB- , pH 7.2 ; 1.5 μl/3 injections / hemisphere -RRB-	15198
both sides	15198
10 % in 0.1 M phosphate-buffered saline -LRB- PBS -RRB-	15210
10 %	15210
0.1 M phosphate-buffered saline -LRB- PBS -RRB-	15217
0.1 M phosphate-buffered saline	15217
PBS	15250
pH 7.2 ; 1.5 μl/3 injections / hemisphere	15256
pH 7.2	15256
1.5 μl/3 injections / hemisphere	15264
1.5 μl/3 injections	15264
hemisphere	15285
The needle	15298
place for 1 min	15321
place	15321
1 min	15331
Histological analysis At 9 weeks after SCI/3 weeks after CS tract tracing	15371
Histological analysis	15371
9 weeks	15396
SCI/3 weeks	15410
CS tract	15428
the rats	15446
an overdose of Nembutal -LRB- 150 mg/kg body weight ; i.p. injection -RRB-	15464
an overdose	15464
Nembutal -LRB- 150 mg/kg body weight ; i.p. injection -RRB-	15479
Nembutal	15479
150 mg/kg body weight	15489
injection	15517
They	15529
ice-cold 4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15568
ice-cold 4 % paraformaldehyde	15568
0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15600
0.1 M phosphate buffer	15600
pH 7.4	15624
perfusion	15639
the spinal cords and the brains	15650
the spinal cords	15650
the brains	15671
post-fixed in cold 4 %	15699
post-fixed	15699
cold 4 %	15713
cold	15713
paraformaldehyde overnight	15730
The following day	15758
the tissue	15777
10 % sucrose in PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15807
10 % sucrose	15807
PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15822
PBS	15822
0.1 M ; pH 7.6	15827
0.1 M	15827
pH 7.6	15834
overnight	15851
4 °C	15864
the tissue	15875
25 % sucrose in PBS	15906
25 % sucrose	15906
PBS	15921
3 days	15938
4 °C	15948
this cryo-protection procedure	15959
the brain and 2.5-cmlong spinal cord pieces including the lesion site	15991
the brain and 2.5-cmlong spinal cord pieces	15991
the lesion site	16045
− 80 °C	16087
a cryostat	16100
the spinal cord pieces	16112
sagittal sections of 25 μm	16154
sagittal sections	16154
25 μm	16175
this way	16186
a total of about 120 sections	16196
a total	16196
about 120 sections	16207
spinal cord	16244
The sections	16257
gelatin chrome-alumn -LRB- Sigma , Uithoorn , The Netherlands -RRB- - coated glass slides	16298
gelatin chrome-alumn	16298
Sigma	16320
Uithoorn	16327
The Netherlands	16337
coated glass slides	16354
− 20 °C	16388
Alternate sections	16395
immunohistochemistry	16433
the following antibodies : mouse anti-p75-NGF receptor -LRB- 1:10,000 ; Chemicon , Hampshire , UK -RRB- , mouse antineurofilament RT97 -LRB- anti-RT97 ; 1:100 ; Hybridoma Bank , Iowa City , IA , USA -RRB- , rabbit anti-GFAP -LRB- 1:1000 ; DAKO -RRB- , rabbit anti-GAP43 / B50 -LRB- generous gift from Leo van Halewijn , Utrecht University , The Netherlands -RRB- , and rabbit-serotonin -LRB- Prof. Dr. H. Steinbusch , Maastricht University , The Netherlands -RRB-	16460
the following antibodies	16460
mouse anti-p75-NGF receptor -LRB- 1:10,000 ; Chemicon , Hampshire , UK -RRB- , mouse antineurofilament RT97 -LRB- anti-RT97 ; 1:100 ; Hybridoma Bank , Iowa City , IA , USA -RRB- , rabbit anti-GFAP -LRB- 1:1000 ; DAKO -RRB- , rabbit anti-GAP43 / B50 -LRB- generous gift from Leo van Halewijn , Utrecht University , The Netherlands -RRB- , and rabbit-serotonin -LRB- Prof. Dr. H. Steinbusch , Maastricht University , The Netherlands -RRB-	16486
mouse anti-p75-NGF receptor -LRB- 1:10,000 ; Chemicon , Hampshire , UK -RRB-	16486
mouse anti-p75-NGF receptor	16486
1:10,000 ; Chemicon , Hampshire , UK	16515
1:10,000	16515
Chemicon , Hampshire , UK	16525
mouse antineurofilament RT97 -LRB- anti-RT97 ; 1:100 ; Hybridoma Bank , Iowa City , IA , USA -RRB-	16551
mouse antineurofilament RT97	16551
anti-RT97 ; 1:100 ; Hybridoma Bank , Iowa City , IA , USA	16581
anti-RT97	16581
1:100 ; Hybridoma Bank , Iowa City , IA , USA	16592
1:100	16592
Hybridoma Bank , Iowa City , IA , USA	16599
Hybridoma Bank	16599
Iowa City	16615
IA	16626
USA	16630
rabbit anti-GFAP -LRB- 1:1000 ; DAKO -RRB-	16636
rabbit anti-GFAP	16636
1:1000 ; DAKO	16654
1:1000	16654
DAKO	16662
rabbit anti-GAP43 / B50 -LRB- generous gift from Leo van Halewijn , Utrecht University , The Netherlands -RRB-	16669
rabbit anti-GAP43 / B50	16669
rabbit anti-GAP43	16669
B50	16687
generous gift from Leo van Halewijn	16692
generous gift	16692
Leo van Halewijn	16711
Utrecht University , The Netherlands	16729
Utrecht University	16729
The Netherlands	16749
rabbit-serotonin -LRB- Prof. Dr. H. Steinbusch , Maastricht University , The Netherlands -RRB-	16771
rabbit-serotonin	16771
Prof. Dr. H. Steinbusch , Maastricht University , The Netherlands	16789
Prof. Dr. H. Steinbusch	16789
Maastricht University	16814
The Netherlands	16837
Secondary antibodies used	16855
Secondary antibodies	16855
streptavidin -- Cy3 -LRB- 1:2000 ; for the BDA-labeled CS axons ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB- , Cy3-conjugated donkey anti-mouse -LRB- 1:800 ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB- , Alexa 488-conjugated goat antimouse -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB- , and Alexa 488-conjugated goat anti-rabbit -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	16886
streptavidin	16886
Cy3 -LRB- 1:2000 ; for the BDA-labeled CS axons ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB- , Cy3-conjugated donkey anti-mouse -LRB- 1:800 ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB- , Alexa 488-conjugated goat antimouse -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB- , and Alexa 488-conjugated goat anti-rabbit -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	16899
Cy3 -LRB- 1:2000 ; for the BDA-labeled CS axons ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB-	16899
Cy3	16899
1:2000 ; for the BDA-labeled CS axons ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK	16904
1:2000	16904
for the BDA-labeled CS axons ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK	16912
the BDA-labeled CS axons	16916
Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK	16942
Jackson ImmunoResearch Europe Ltd.	16942
Cambridgeshire , UK	16978
Cy3-conjugated donkey anti-mouse -LRB- 1:800 ; Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK -RRB-	16999
Cy3-conjugated donkey anti-mouse	16999
1:800 ; Jackson ImmunoResearch Europe Ltd.	17033
1:800	17033
Jackson ImmunoResearch Europe Ltd.	17040
Cambridgeshire , UK	17076
Cambridgeshire	17076
UK	17092
Alexa 488-conjugated goat antimouse -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	17097
Alexa 488-conjugated goat antimouse	17097
1:100 ; Molecular Probes/Invitrogen	17134
1:100	17134
Molecular Probes/Invitrogen	17141
Breda , The Netherlands	17170
Breda	17170
The Netherlands	17177
Alexa 488-conjugated goat anti-rabbit -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	17199
Alexa	17199
488-conjugated goat anti-rabbit -LRB- 1:100 ; Molecular Probes/Invitrogen , Breda , The Netherlands -RRB-	17205
488-conjugated goat anti-rabbit	17205
1:100 ; Molecular Probes/Invitrogen	17238
1:100	17238
Molecular Probes/Invitrogen	17245
Breda , The Netherlands	17274
Breda	17274
The Netherlands	17281
Antibodies	17299
0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	17326
0.3 % Triton X-100	17326
Tris-buffered saline -LRB- TBS-T -RRB-	17347
Tris-buffered saline	17347
TBS-T	17369
All primary antibody incubations	17377
overnight at room temperature	17415
overnight	17415
room temperature	17428
All secondary antibody incubations	17446
1.5 h at room temperature	17486
1.5 h	17486
room temperature	17495
double staining protocols	17516
the primary antibodies	17543
a mixture	17579
the incubation with the Cy3-labeled secondary antibody	17593
the incubation	17593
the Cy3-labeled secondary antibody	17613
the incubation	17664
the Alexalabeled secondary antibody	17684
all antibody incubations	17728
the washing steps	17754
10 min TBS-T , 10 min TBS -LRB- TBS-T without Triton X-100 -RRB- , and 10 min TBS-T	17785
10 min TBS-T	17785
10 min TBS	17799
TBS-T without Triton X-100	17811
TBS-T	17811
Triton X-100	17825
10 min TBS-T	17844
All other washing steps	17858
All other	17858
steps	17876
three times 10 min TBS	17891
three times	17891
10 min TBS	17903
Hoechst stainings	17919
a 30-min incubation in Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB-	17938
a 30-min incubation in Hoechst 33342	17938
a 30-min incubation	17938
Hoechst 33342	17961
Sigma	17976
Uithoorn	17983
The Netherlands	17993
Every sixth section	18020
p75	18056
p75 and Hoechst , GFAP / BDA-labeled CS axons , GAP43/BDA-labeled CS axons , GFAP / neurofilament , or GFAP/serotonin	18083
p75 and Hoechst	18083
p75	18083
Hoechst	18091
GFAP / BDA-labeled CS axons , GAP43/BDA-labeled CS axons , GFAP / neurofilament	18100
GFAP	18100
BDA-labeled CS axons , GAP43/BDA-labeled CS axons , GFAP	18106
BDA-labeled CS axons	18106
GAP43/BDA-labeled CS axons	18128
GFAP	18156
neurofilament	18162
GFAP/serotonin	18180
Stained sections	18196
an Olympus AX-70 microscope using epifluorescent illumination	18233
an Olympus AX-70 microscope	18233
epifluorescent illumination	18267
The microscope	18296
a × 20 objective and a × 10 projection lens	18329
a × 20 objective	18329
a × 10 projection lens	18349
The signal for Alexa 488 -LRB- green -RRB-	18372
The signal for Alexa 488	18372
The signal	18372
Alexa 488	18387
a narrow band MNIBA-type FITC filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18424
a narrow band MNIBA-type FITC filter	18424
Chroma Technology Corp	18462
Rockingham	18486
VT , USA	18498
the signal for Cy3 -LRB- red -RRB-	18508
the signal	18508
Cy3 -LRB- red -RRB-	18523
Cy3	18523
red	18528
a MNG filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18552
a MNG filter	18552
Chroma Technology Corp	18566
Rockingham	18590
VT , USA	18602
the signal for Hoechst -LRB- blue -RRB-	18616
the signal for Hoechst	18616
the signal	18616
Hoechst	18631
a U-MNIBA filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18665
a U-MNIBA filter	18665
Chroma Technology Corp	18683
Rockingham	18707
VT , USA	18719
Pictures of the stained sections were made at a magnification of × using a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	18729
Pictures	18729
the stained sections were made at a magnification of × using a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	18741
the	18741
sections	18753
a magnification of ×	18775
a magnification	18775
×	18794
a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	18801
a Sony Power HAD 3CCD Color Video Camera	18801
an Olympus F-view	18845
CCD camera -LRB- Paes , Zoeterwoude , The Netherlands -RRB-	18870
CCD camera	18870
Paes	18882
Zoeterwoude	18888
The Netherlands	18901
All pictures	18919
the image analyzing system analySIS Vers	18951
the image	18951
system analySIS Vers	18971
3.0	18993
Soft Imaging System , Münster ,	18999
Soft Imaging System	18999
Münster	19020
Quantitative analysis CS axon growth All sections with BDA-labeled CS axons	19040
Quantitative analysis CS	19040
axon growth	19065
All sections with BDA-labeled CS axons	19077
All sections	19077
BDA-labeled CS axons	19095
quantitative analysis	19135
250-μm-wide boxes	19158
four different locations in the spinal cord sections	19191
four different locations	19191
the spinal cord sections	19219
indications in Fig. 4	19254
indications	19254
Fig. 4	19269
The first box	19278
the dorsal gray/white matter at 2.5 -- 3 mm rostral to the injury site	19306
the dorsal gray/white matter at 2.5	19306
the dorsal gray/white matter	19306
2.5	19338
3 mm rostral to the injury site	19342
3 mm rostral	19342
the injury site	19358
the rostral reference	19394
The second box	19418
the dorsal gray/white matter directly rostral	19447
the dorsal gray/white matter	19447
the injury site	19496
The third box	19513
the gray matter underneath the lesion site	19541
the gray matter	19541
the lesion site	19568
only few axons	19591
the lesion site	19630
the box	19647
the area where most BDA immunoreactivity was found	19669
the area	19669
most BDA immunoreactivity	19684
The fourth box	19721
the gray matter caudal	19750
the injury site	19776
the position where most BDA immunoreactivity could be found	19802
the position	19802
most BDA immunoreactivity	19821
The few BDA-immunoreactive CS axons	19863
the caudal gray matter within 10 mm	19931
the caudal gray matter	19931
10 mm	19961
the caudal edge of the lesion site	19972
the caudal edge	19972
the lesion site	19991
All four boxes	20008
all the sections containing BDA-labeled CS axons	20040
all the sections	20040
BDA-labeled CS axons	20068
The percentage of each box occupied by BDA-immunoreactive axons -LRB- `` BDA immunoreactivity occupation '' -RRB-	20090
The percentage	20090
each box occupied by BDA-immunoreactive axons -LRB- `` BDA immunoreactivity occupation '' -RRB-	20108
each box	20108
BDA-immunoreactive axons -LRB- `` BDA immunoreactivity occupation '' -RRB-	20129
BDA-immunoreactive axons	20129
BDA	20156
immunoreactivity occupation ''	20160
immunoreactivity	20160
occupation ''	20177
the box values in all the sections	20208
the box values	20208
all the sections	20226
the efficiency of BDA CS tract tracing	20262
the efficiency	20262
BDA CS tract tracing	20280
BDA CS tract	20280
animals	20327
the BDA immunoreactivity at the rostral reference	20336
the BDA immunoreactivity	20336
the rostral reference	20364
the 100 % reference value of BDA-labeled axons of each animal	20399
the 100 % reference value	20399
BDA-labeled axons of each animal	20427
BDA-labeled axons	20427
each animal	20448
The BDA immunoreactivity values of boxes 2 , 3 , and 4	20461
The BDA immunoreactivity values	20461
boxes 2 , 3 , and 4	20496
boxes	20496
2 , 3 , and 4	20502
that of the rostral reference	20541
that	20541
the rostral reference	20549
A similar quantification method	20572
others -LRB- Goldshmit et al. , 2004 -RRB-	20637
others	20637
Goldshmit	20645
et al. , 2004	20655
et al.	20655
2004	20663
Double staining CS axons and GAP43/B50 All sections double-stained for CS axons and GAP43/B50	20670
Double staining CS axons	20670
GAP43/B50 All sections double-stained for CS axons and GAP43/B50	20699
GAP43/B50	20699
All sections double-stained for CS axons and GAP43/B50	20709
All sections	20709
CS axons and GAP43/B50	20741
BDA-labeled CS axons	20792
transplanted and/or control animals	20845
transplanted	20845
control animals	20865
Axon growth into the lesion/graft site Every sixth section of five transplanted and five control animals	20882
Axon growth	20882
the lesion/graft site Every sixth section of five transplanted and five control animals	20899
the lesion/graft site	20899
Every sixth section of five transplanted and five control animals	20921
Every sixth section	20921
five transplanted and five control animals	20944
five transplanted	20944
five control animals	20966
GFAP and neurofilament	21010
the degree of neurofilament-positive axon growth	21053
the degree	21053
neurofilament-positive axon growth	21067
the lesion/graft site	21107
Similar to the quantitative analysis of the BDA-labeled CS tract , the neurofilament immunoreactivity within the total lesion/graft site	21130
Similar	21130
the quantitative analysis of the BDA-labeled CS tract , the neurofilament immunoreactivity within the total lesion/graft site	21141
the quantitative analysis	21141
the BDA-labeled CS tract , the neurofilament immunoreactivity within the total lesion/graft site	21170
the BDA-labeled CS tract	21170
the neurofilament immunoreactivity within the total lesion/graft site	21196
the neurofilament immunoreactivity	21196
the total lesion/graft site	21238
GFAP staining	21280
the lesion / graft site	21326
the lesion	21326
graft site	21338
the percentage of the total lesion/graft site occupied by neurofilament immunoreactivity -LRB- `` NF immunoreactivity occupation '' -RRB-	21357
the percentage	21357
the total lesion/graft site occupied by neurofilament immunoreactivity -LRB- `` NF immunoreactivity occupation '' -RRB-	21375
the total lesion/graft site	21375
neurofilament immunoreactivity -LRB- `` NF immunoreactivity occupation '' -RRB-	21415
neurofilament immunoreactivity	21415
NF	21448
immunoreactivity occupation ''	21451
immunoreactivity	21451
occupation ''	21468
all sections	21506
transplanted and control animals	21541
transplanted	21541
control animals	21558
raphespinal axons	21607
the axons	21636
the graft/lesion site	21658
a double staining of GFAP/serotonin	21681
a double staining	21681
GFAP/serotonin	21702
Functional testing Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale This locomotor test assesses locomotor performance of the hind limbs via a score that ranges from 0 to 21 -LRB- Basso et al. , 1995 -RRB- .	21732
Functional testing	21732
Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	21751
Basso -- Beattie -- Bresnahan	21751
Beattie	21757
BBB	21776
locomotor rating scale This locomotor test assesses locomotor performance	21781
locomotor rating scale	21781
This locomotor test	21804
locomotor performance	21833
the hind limbs	21858
a score that ranges from 0 to 21 -LRB- Basso et al. , 1995 -RRB-	21877
a score	21877
0 to 21	21902
Basso	21911
et al. , 1995	21917
et al.	21917
1995	21925
The BBB test	21932
the recommendations with an observation time of approximately 4 min and by two investigators which were blind to the treatment	21972
the recommendations	21972
an observation time of approximately 4 min	21997
an observation time	21997
approximately 4 min	22020
two investigators which were blind to the treatment	22047
two investigators	22047
the treatment	22085
The scores of the left and right hind limbs	22100
The scores	22100
the left and right hind limbs	22114
the BBB score of the animal	22171
the BBB score	22171
the animal	22188
The BBB test	22200
the day of the operation	22245
the day	22245
the operation	22256
the following days postoperatively -LRB- DPO -RRB-	22277
the following days postoperatively	22277
the following days	22277
DPO	22313
1 , 2 , 3 , 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , and 63	22319
1	22319
2	22322
3	22325
7	22328
14	22331
21	22335
28	22339
35	22343
42	22347
49 , 56 , and 63	22351
CatWalk gait analysis This locomotor test	22367
CatWalk gait analysis	22367
This locomotor test	22389
an easy and objective analysis of both static and dynamic locomotor parameters , such as stride length , base of support , interlimb coordination ,	22416
an easy and objective analysis	22416
both static and dynamic locomotor parameters	22450
stride length , base of support , interlimb coordination ,	22504
stride length	22504
base of support , interlimb coordination ,	22519
base	22519
support , interlimb coordination ,	22527
support	22527
interlimb coordination	22536
/ stance phases	22569
stance	22571
Details on the CatWalk set-up	22586
Details	22586
the CatWalk set-up	22597
Hamers et al. , 2001 ; Koopmans et al. , 2005	22640
Hamers	22640
et al. , 2001 ; Koopmans et al. , 2005	22647
et al. , 2001	22647
et al.	22647
2001	22655
Koopmans et al. , 2005	22661
Koopmans	22661
et al. , 2005	22670
et al.	22670
2005	22678
the animals	22694
about 2 weeks	22722
a glass runway	22745
hesitation	22768
this training period	22787
the animals	22809
the CatWalk test via a 12 g/day food restriction protocol	22840
the CatWalk test	22840
a 12 g/day food restriction protocol	22861
24 h before testing	22902
24 h	22902
testing	22914
the animals	22923
food	22952
Small food pellets	22958
Noyes Precision	22978
PJPPP-0045 ; Sandown Chemical Ltd. , Hampton , UK	23002
PJPPP-0045	23002
Sandown Chemical Ltd. , Hampton , UK	23014
Sandown Chemical Ltd.	23014
Hampton , UK	23037
located at the end of the glass runway	23050
the end of the glass	23061
the end	23061
the glass	23072
a reward	23102
analysis	23116
three uninterrupted runs	23126
CatWalk-based BBB scale	23162
Koopmans et al. , 2005	23211
Koopmans	23211
et al.	23220
2005	23228
the coordination parameter obtained from the CatWalk , the regularity index -LRB- RI -RRB- ,	23235
the coordination parameter	23235
the CatWalk , the regularity index -LRB- RI -RRB- ,	23276
the CatWalk	23276
the regularity index -LRB- RI -RRB-	23289
the regularity index	23289
RI	23311
the BBB scoring	23340
the BBB	23340
brief	23360
the RI grades	23367
the degree of coordination as the number of normal step sequence patterns multiplied by four , divided by the total number of paw placements and multiplied by 100 %	23381
the degree	23381
coordination as the number of normal step sequence patterns multiplied by four , divided by the total number of paw placements and multiplied by 100 %	23395
coordination	23395
the number of normal step sequence patterns multiplied by four , divided by the total number of paw placements and multiplied by 100 %	23411
the number	23411
normal step sequence patterns multiplied by four , divided by the total number of paw placements and multiplied by 100 %	23425
normal step sequence patterns	23425
four	23469
the total number of paw placements	23486
the total number	23486
paw placements	23506
100 %	23539
Koopmans et al. , 2005	23545
Koopmans	23545
et al.	23554
2005	23562
Crossings of the glass runway with an RI of 100 %	23569
Crossings	23569
the glass runway with an RI of 100 %	23582
the glass runway	23582
an RI of 100 %	23604
an RI	23604
100 %	23613
three , two , one , or none of the CatWalk	23649
three	23649
two	23656
one	23661
none of the CatWalk	23669
none	23669
the CatWalk	23677
no coordination	23747
the BBB score of the animal at that testing day , respectively -LRB- Koopmans et al. , 2005 -RRB-	23788
the BBB score	23788
the animal at that testing day , respectively -LRB- Koopmans et al. , 2005 -RRB-	23805
the animal at that testing day , respectively	23805
the animal at that testing day	23805
the animal	23805
that testing day	23819
Koopmans	23851
et al. , 2005	23860
et al.	23860
2005	23868
Results	23876
1	23890
Hoechst-prelabeled OEC/ONF	23906
host cells	23950
the lesion site	23966
One day	23983
transplantation	24000
OEC/ONF	24017
Hoechst 33342	24046
-LRB- A -RRB- S100β immunostained and Hoechst-prelabeled OEC/ONF fixed at the day of transplantation -LRB- examples of S100β immunostaining -LRB- arrowheads -RRB- and Hoechst staining -LRB- arrows -RRB-	24061
-LRB- A -RRB- S100β immunostained and Hoechst-prelabeled OEC/ONF	24061
-LRB- A -RRB-	24061
S100β immunostained and Hoechst-prelabeled OEC/ONF	24065
the day of transplantation -LRB- examples of S100β immunostaining -LRB- arrowheads -RRB- and Hoechst staining -LRB- arrows -RRB-	24125
the day	24125
transplantation -LRB- examples of S100β immunostaining -LRB- arrowheads -RRB- and Hoechst staining -LRB- arrows -RRB-	24136
transplantation -LRB- examples of S100β immunostaining -LRB- arrowheads -RRB-	24136
transplantation	24136
examples of S100β immunostaining -LRB- arrowheads -RRB-	24153
examples	24153
S100β immunostaining -LRB- arrowheads -RRB-	24165
S100β immunostaining	24165
arrowheads	24187
Hoechst staining -LRB- arrows -RRB-	24203
Hoechst staining	24203
arrows	24221
-LRB- B , C -RRB- Prelabeled OEC/ONF present in a limited area -LRB- around the injection site -RRB- rostral to the injury site at 9 weeks after injury/transplantation .	24244
-LRB- B , C -RRB- Prelabeled OEC/ONF	24244
B , C	24245
B	24245
C	24248
a limited area -LRB- around the injection site -RRB- rostral	24281
the injection site	24304
the injury site at 9 weeks after injury/transplantation	24335
the injury site	24335
9 weeks after injury/transplantation	24354
9 weeks	24354
injury/transplantation	24368
The dotted line in panel B	24392
The dotted line	24392
panel B	24411
the spinal cord	24430
the arrow	24447
the location of the lesion site ; d , dorsal ; v , ventral ; r , rostral ; c , caudal ; panel C is an enlargement of the box shown in panel B. -LRB- D -RRB- Transplanted Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area ; note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24467
the location of the lesion site ; d , dorsal ; v , ventral ; r , rostral ; c , caudal	24467
the location of the lesion site	24467
the location	24467
the lesion site	24483
d , dorsal	24500
d	24500
dorsal	24503
v , ventral	24511
v	24511
ventral	24514
r , rostral	24523
r	24523
rostral	24526
c , caudal	24535
c	24535
caudal	24538
panel C	24546
an enlargement of the box shown in panel B. -LRB- D -RRB- Transplanted Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area ; note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24557
an enlargement	24557
the box shown in panel B. -LRB- D -RRB- Transplanted Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area ; note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24575
the box	24575
panel B. -LRB- D -RRB- Transplanted Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area ; note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24592
panel B.	24592
D	24602
Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area ; note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24618
Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area	24618
Hoechst-prelabeled cells -LRB- blue -RRB-	24618
Hoechst-prelabeled cells	24618
blue	24644
the injection area	24653
note that a proportion of the cells are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24673
note	24673
a proportion of the cells	24683
a proportion	24683
the cells	24699
p75-NGF receptor -LRB- red -RRB-	24732
p75-NGF receptor	24732
red	24750
Arrows	24756
a few Hoechst-prelabeled cells with p75-NGF receptor immunoreactivity	24772
a few Hoechst-prelabeled cells	24772
p75-NGF receptor immunoreactivity	24808
-LRB- E -RRB- Hoechst staining of the OEC/ONF -- biomatrix complex within the lesion site ; all these Hoechst-positive cells	24843
-LRB- E -RRB-	24843
Hoechst	24847
staining of the OEC/ONF -- biomatrix complex within the lesion site ; all these Hoechst-positive cells	24855
staining of the OEC/ONF	24855
staining	24855
the OEC/ONF	24867
biomatrix complex within the lesion site	24879
biomatrix complex	24879
the lesion site	24904
all these Hoechst-positive cells	24921
all	24921
these Hoechst-positive cells	24925
host cells -LRB- note that the Hoechst staining does not reflect any prelabeled cells , but only cells that are labeled after sacrificing the animals -RRB-	24971
host cells	24971
note that the Hoechst staining does not reflect any prelabeled cells , but only cells that are labeled after sacrificing the animals	24983
note	24983
the Hoechst staining	24993
any prelabeled cells , but only cells that are labeled after sacrificing the animals	25031
any prelabeled cells	25031
cells that are labeled after sacrificing the animals	25062
cells	25062
the animals	25103
-LRB- F -RRB- Identification of infiltrating Hoechst-stained -LRB- blue -RRB- host cells within the biomatrix complex ; a subpopulation of the cells	25117
-LRB- F -RRB- Identification of infiltrating Hoechst-stained -LRB- blue -RRB- host cells within the biomatrix complex	25117
Identification	25121
Hoechst-stained -LRB- blue -RRB- host cells	25152
the biomatrix complex	25193
a subpopulation of the cells	25216
a subpopulation	25216
the cells	25235
p75-NGF receptor -LRB- red -RRB-	25267
p75-NGF receptor	25267
red	25285
Scale bars in A -- C , E , and F	25291
Scale bars	25291
A -- C , E , and F	25305
C , E , and F	25307
C	25307
E	25310
F	25317
200 μm	25323
scale bar in panel D	25331
scale bar	25331
panel D	25344
100 μm	25355
Fig. 2 .	25364
Fig.	25364
2	25369
Transplantation of OEC/ONF-biomatrix complexes in dorsal hemisection injury sites .	25372
Transplantation	25372
OEC/ONF-biomatrix complexes	25391
dorsal hemisection injury sites	25422
a laminectomy of the low-thoracic spinal cord -LRB- A -RRB-	25461
a laminectomy	25461
the low-thoracic spinal cord -LRB- A -RRB-	25478
the low-thoracic spinal cord	25478
A	25508
a 2-mm-long dorsal hemisection gap	25512
B	25557
Hereafter , OEC/ONF suspensions	25561
Hereafter	25561
OEC/ONF suspensions	25572
1 mm rostral and 1 mm caudal to the injury site -LRB- approximate injection sites are indicated by arrowheads -RRB- and an aligned OEC/ONF	25609
1 mm rostral and 1 mm caudal to the injury site	25609
1 mm rostral	25609
1 mm caudal to the injury site	25626
1 mm caudal	25626
the injury site	25641
approximate injection sites	25658
arrowheads	25703
an aligned OEC/ONF	25719
biomatrix complex	25738
the lesion gap -LRB- C -RRB-	25774
the lesion gap	25774
C	25790
This complex	25794
a Dura Film covering -LRB- not shown -RRB-	25825
a Dura Film	25825
Fig. 3 .	25859
Fig.	25859
3	25864
Neurofilament IR fiber ingrowth into the graft/lesion site .	25867
Neurofilament IR fiber ingrowth	25867
the graft/lesion site	25904
The graft/lesion site	25927
the schematic representation in panel A	25980
the schematic representation	25980
panel A	26012
the asterisk in panel A	26021
the asterisk	26021
panel A	26037
the approximate location of the section shown in panel B. GFAP immunostaining was used to identify the border of the graft/lesion site	26056
the approximate location	26056
the section shown in panel B. GFAP immunostaining was used to identify the border of the graft/lesion site	26084
the section	26084
panel B. GFAP immunostaining was used to identify the border of the graft/lesion site	26105
panel	26105
B. GFAP immunostaining	26111
the border of the graft/lesion site	26155
the border	26155
the graft/lesion site	26169
Numerous neurofilament IR fibers	26192
the GFAP-IR tissue -LRB- arrow in panel B -RRB-	26247
the GFAP-IR tissue	26247
arrow in panel B	26267
arrow	26267
panel B	26276
the graft/lesion site -LRB- B -RRB-	26299
the graft/lesion site	26299
B	26322
control animals	26329
neurofilament IR fibers	26346
the GFAP-IR tissue	26382
the outer circumferences of the lesion gap	26420
the outer circumferences	26420
the lesion gap	26448
Quantification of neurofilament IR fiber ingrowth into the graft/lesion site	26464
Quantification	26464
neurofilament IR fiber ingrowth into the graft/lesion site	26482
neurofilament IR fiber ingrowth	26482
the graft/lesion site	26519
a 10-fold increase	26548
transplanted versus control animals -LRB- C -RRB-	26570
transplanted	26570
control animals -LRB- C -RRB-	26590
control animals	26590
C	26607
Serotonin immunohistochemistry	26611
serotonergic fibers	26653
the graft/lesion site -LRB- indicated with an asterisk -RRB- -LRB- D -RRB-	26682
the graft/lesion site -LRB- indicated with an asterisk -RRB-	26682
the graft/lesion site	26682
an asterisk	26720
D	26734
Arrowheads in panel B	26738
Arrowheads	26738
panel B	26752
parts of the PLA/PLA-b-PEO biomatrix material ; R , rostral ; C , caudal	26769
parts of the PLA/PLA-b-PEO biomatrix material	26769
parts	26769
the PLA/PLA-b-PEO biomatrix material	26778
R , rostral	26816
R	26816
rostral	26819
C , caudal	26828
C	26828
caudal	26831
P <	26840
P	26840
<	26842
0.05	26844
Fig. 4 .	26851
Fig.	26851
4	26856
BDA-IR corticospinal axon response to OEC/ONF intervention .	26859
BDA-IR	26859
corticospinal axon response to OEC/ONF intervention	26866
corticospinal axon response	26866
OEC/ONF intervention	26897
BDA-IR corticospinal axons	26919
the graft/lesion site	26972
very few	27004
the lesion	27029
the caudal host	27049
spinal cord	27065
No labeled corticospinal axons	27078
the graft/lesion site	27120
-LRB- A -RRB- Sagittal spinal cord section of an OEC/ONF-transplanted animal .	27143
-LRB- A -RRB-	27143
Sagittal spinal cord section of an OEC/ONF-transplanted animal	27147
Sagittal spinal cord section	27147
an OEC/ONF-transplanted animal	27179
The dotted line	27211
the delineation of the spinal cord	27238
the delineation	27238
the spinal cord	27257
the OEC/ONF -- biomatrix complex	27274
the OEC/ONF	27274
biomatrix complex	27286
the lesion site	27322
The four boxes	27339
the boxes used in the quantitative analysis	27364
the boxes	27364
the quantitative analysis	27382
-LRB- B -RRB- A significantly higher BDA-IR is present directly rostral to the injury site -LRB- box 2 -RRB- in transplanted animals versus control animals .	27409
-LRB- B -RRB- A significantly higher BDA-IR is present directly	27409
-LRB- B -RRB-	27409
A significantly higher BDA-IR	27413
rostral to the injury site -LRB- box 2 -RRB- in transplanted animals versus control animals	27463
rostral	27463
the injury site -LRB- box 2 -RRB- in transplanted animals versus control animals	27474
the injury site -LRB- box 2 -RRB-	27474
the injury site	27474
box 2	27491
transplanted animals versus control animals	27501
transplanted animals	27501
control animals	27529
BDA/GFAP-stained sagittal section of an OEC/ONF-transplanted animal ; many BDA-labeled corticospinal axons	27550
BDA/GFAP-stained sagittal section	27550
an OEC/ONF-transplanted animal ; many BDA-labeled corticospinal axons	27587
an OEC/ONF-transplanted animal	27587
many BDA-labeled corticospinal axons	27619
rostral	27661
the graft/lesion site	27672
asterisk in panel C	27695
asterisk	27695
panel C	27707
the graft/lesion site	27725
D , E	27749
D	27749
E	27752
BDA/GAP43-stained sagittal sections of OEC/ONF-transplanted animals showing that labeled corticospinal axons rostral to the graft/lesion site	27755
BDA/GAP43-stained sagittal sections	27755
OEC/ONF-transplanted animals showing that labeled corticospinal axons rostral to the graft/lesion site	27794
OEC/ONF-transplanted animals	27794
corticospinal axons rostral	27844
the graft/lesion site	27875
GAP43 IR -LRB- D -RRB-	27905
GAP43 IR	27905
D	27915
numerous GAP43 IR fibers	27923
the graft/lesion site -LRB- note that panel E is in the middle of the graft/lesion site -RRB-	27967
the graft/lesion site	27967
note that panel E is in the middle of the graft/lesion site	27990
note	27990
panel E	28000
the middle of the graft/lesion site	28014
the middle	28014
the graft/lesion site	28028
E	28052
asterisk in panel D	28056
asterisk	28056
panel D	28068
the graft/lesion site	28086
-LRB- F -RRB- BDA-labeled corticospinal axon -LRB- arrow -RRB- present within the caudal gray matter of an OEC/ONF-transplanted animal ; these caudal fibers	28109
-LRB- F -RRB- BDA-labeled corticospinal axon -LRB- arrow -RRB-	28109
-LRB- F -RRB- BDA-labeled corticospinal axon	28109
-LRB- F -RRB-	28109
BDA-labeled corticospinal axon	28113
arrow	28145
the caudal gray matter of an OEC/ONF-transplanted animal ; these caudal fibers	28167
the caudal gray matter of an OEC/ONF-transplanted animal	28167
the caudal gray matter	28167
an OEC/ONF-transplanted animal	28193
these caudal fibers	28225
one or two transplanted and control animals	28264
one	28264
two transplanted and control animals	28271
two transplanted	28271
control animals	28292
Scale bars	28309
100 μm	28324
Fig. 5 .	28333
Fig.	28333
5	28338
Behavioral effects of OEC/ONF intervention .	28341
Behavioral effects	28341
OEC/ONF intervention	28363
The acute OEC/ONF transplantation	28385
an effect on gross locomotion	28432
an effect	28432
gross locomotion	28445
the outcome of the BBB locomotor scale -LRB- A -RRB- and the CatWalk-based BBB scale -LRB- B -RRB-	28478
the outcome	28478
the BBB locomotor scale -LRB- A -RRB- and the CatWalk-based BBB scale -LRB- B -RRB-	28493
the BBB locomotor scale	28493
A	28518
the CatWalk-based BBB scale	28525
B	28554
Fine locomotor parameters as assessed in the CatWalk gait analysis showed a significant difference after acute OEC/ONF transplantation at 9 weeks after injury : stride length and swing speed of the hind limbs	28558
Fine locomotor parameters	28558
the CatWalk gait analysis	28599
a significant difference	28632
acute OEC/ONF transplantation at 9 weeks	28663
acute OEC/ONF transplantation	28663
9 weeks	28696
injury : stride length	28710
injury	28710
stride length	28718
speed of the hind limbs	28742
speed	28742
the hind limbs	28751
transplanted versus control animals -LRB- C , D -RRB-	28797
transplanted	28797
control animals -LRB- C , D -RRB-	28817
control animals	28817
P < 0.05 .	28842
P	28842
< 0.05 .	28844
<	28844
0.05 .	28846
OEC/ONF cultures The mixed OEC/ONF cultures	28853
OEC/ONF cultures	28853
The mixed OEC/ONF cultures	28870
those described previously -LRB- Li et al. , 1998 -RRB-	28915
those	28915
Li et al. , 1998	28943
Li	28943
et al.	28946
1998	28954
The cultures	28961
two main cell populations : the OEC and the ONF	28984
two main cell populations	28984
the OEC and the ONF	29011
the OEC	29011
the ONF	29023
The OEC population	29032
spindle-shaped cells co-expressing p75-NGF receptor and S100β	29072
spindle-shaped cells	29072
p75-NGF receptor and S100β	29107
OEC	29148
the GFAP protein	29162
The ONF population	29211
multiple cell types	29243
a flattened fibroblast-like morphology	29268
Immunoreactivity for fibronectin and GFAP in the ONF population	29308
Immunoreactivity	29308
fibronectin and GFAP in the ONF population	29329
fibronectin and GFAP	29329
the ONF population	29353
the presence of fibroblasts and astrocytes	29382
the presence	29382
fibroblasts and astrocytes	29398
the time in culture	29453
the time	29453
culture	29465
the relative contribution of OEC/ONF	29474
the relative contribution	29474
OEC/ONF	29503
Deumens et al. , 2004	29522
Deumens	29522
et al.	29530
2004	29538
which	29545
either a higher ONF proliferation as compared toOEC or a down-regulation of the p75 - NGF receptor by OEC	29563
either a higher ONF proliferation as compared toOEC	29563
either a higher ONF proliferation	29563
toOEC	29609
a down-regulation of the p75 - NGF receptor by OEC	29618
a down-regulation of the p75	29618
a down-regulation	29618
the p75	29639
NGF receptor by OEC	29648
NGF receptor	29648
OEC	29664
advancing time in the presence of serum in the culture medium as previously suggested -LRB- Franceschini and Barnett , 1996 -RRB-	29673
advancing time	29673
the presence of serum in the culture medium as previously suggested -LRB- Franceschini and Barnett , 1996 -RRB-	29691
the presence	29691
serum in the culture medium as previously suggested -LRB- Franceschini and Barnett , 1996 -RRB-	29707
serum	29707
the culture medium as previously suggested -LRB- Franceschini and Barnett , 1996 -RRB-	29716
the culture medium	29716
Franceschini and Barnett	29760
1996	29786
the time of transplantation -LRB- i.e. after 14 days in vitro -RRB-	29796
the time	29796
transplantation -LRB- i.e. after 14 days in vitro -RRB-	29808
transplantation	29808
i.e. after 14 days in vitro	29825
i.e.	29825
14 days in vitro	29836
14 days	29836
the cultures	29855
10 % OEC	29884
selective immunostaining for either S100β or p75-NGF receptor	29902
selective immunostaining	29902
either S100β or p75-NGF receptor	29931
S100β	29938
p75-NGF receptor	29947
Prelabeling of the OEC/ONF cultures with Hoechst 1 day prior to transplantation	29965
Prelabeling	29965
the OEC/ONF cultures with Hoechst 1 day prior to transplantation	29980
the OEC/ONF cultures	29980
Hoechst	30006
1 day	30014
transplantation	30029
all the cells	30063
the presence of a stained -LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30098
the presence	30098
a stained -LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30114
a	30114
-LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30124
-LRB- blue -RRB- nucleus	30124
Fig. 1A	30140
SCI , transplantation Eighteen animals	30150
SCI	30150
transplantation Eighteen animals	30155
transplantation	30155
Eighteen animals	30171
a 2-mm-long dorsal hemisection injury	30197
T11/T12 -LRB- Fig. 2 -RRB-	30238
T11/T12	30238
Fig. 2	30247
Ten animals	30256
an OEC/ONF -- biomatrix that completely filled the lesion gap -LRB- Fig. 2 -RRB- and additionally received OEC/ONF injections into the host tissue rostral and caudal to this lesion gap	30285
an OEC/ONF	30285
biomatrix that completely filled the lesion gap -LRB- Fig. 2 -RRB- and additionally received OEC/ONF injections into the host tissue rostral and caudal to this lesion gap	30296
biomatrix	30296
the lesion gap -LRB- Fig. 2 -RRB-	30329
the lesion gap	30329
Fig. 2	30345
OEC/ONF injections	30379
the host tissue rostral and caudal	30403
the host tissue rostral	30403
caudal	30431
this lesion gap	30441
Eight control animals	30458
culture medium injections	30494
the same locations	30523
the host tissue	30545
all eighteen animals	30571
a significant drop	30599
body weight	30621
5 %	30640
the first week postoperatively	30647
the first week	30647
they	30679
body weight	30695
the weeks	30710
the two groups of animals	30745
the two groups	30745
animals	30763
a significant difference in body weight	30787
a significant difference	30787
body weight	30815
any time point in the study -LRB- data not shown -RRB-	30830
any time point	30830
the study -LRB- data not shown -RRB-	30848
the study	30848
data not shown	30859
data	30859
Transplants within the spinal cord	30876
Transplants	30876
the spinal cord	30895
9 weeks	30914
the SCI and acute transplantation or control intervention	30928
the SCI	30928
acute transplantation or control intervention	30940
the animals	30987
the time of dissecting the paraformaldehyde-fixed spinal cords from the transplanted animals	31019
the time	31019
the paraformaldehyde-fixed spinal cords from the transplanted animals	31042
the paraformaldehyde-fixed spinal cords	31042
the transplanted animals	31087
the OEC/ONF -- biomatrix complexes	31113
the OEC/ONF	31113
biomatrix complexes	31125
the lesion sites	31169
a stiff connective tissue bridge	31200
the graft/lesion site	31241
This connective tissue complicated the procedure of taking the	31264
This connective tissue	31264
the procedure of taking the	31299
the procedure	31299
the	31323
spinal cord	31335
the animals	31354
this procedure	31376
much care	31412
histological analysis of sagittal spinal cord sections	31423
histological analysis	31423
sagittal spinal cord sections	31448
the OEC/ONF -- biomatrix complex	31490
the OEC/ONF	31490
biomatrix complex	31502
a large extent disconnected from the host spinal tissue in many animals	31527
a large extent	31527
the host spinal tissue in many animals	31560
the host spinal tissue	31560
many animals	31586
a disconnection	31609
the complex and the underlying host spinal tissue	31652
the complex	31652
the underlying host spinal tissue	31668
a disconnection between the complex and the rostral and caudal host tissue	31703
a disconnection	31703
the complex and the rostral and caudal host tissue	31727
the complex	31727
the rostral and caudal host tissue	31743
nearly all transplanted animals	31791
many complex remnants	31837
the inner of the complexes	31880
the inner	31880
the complexes	31893
partly complex degradation	31919
control animals	31950
the lesion site	31967
any tissue	31997
Hoechst-prelabeled OEC/ONF	32022
the levels of the rostral and caudal injection sites	32074
the levels	32074
the rostral and caudal injection sites	32088
the rostral	32088
caudal injection sites	32104
none	32132
the biomatrix complexes	32158
The Hoechst-prelabeled OEC/ONF rostral and caudal to the lesion gap	32183
The Hoechst-prelabeled OEC/ONF rostral and caudal	32183
the lesion gap	32236
a relatively small area of the spinal cord	32273
a relatively small area	32273
the spinal cord	32300
the injection sites	32335
little or no migration into the surrounding host tissue -LRB- Figs. 1B -- D -RRB-	32361
little or no migration	32361
the surrounding host tissue	32389
Figs. 1B -- D	32418
Figs. 1B	32418
D	32427
many yellowish crystalloid autofluorescent macrophages -LRB- Bunn et al. , 2002 -RRB-	32440
many yellowish crystalloid autofluorescent macrophages	32440
Bunn	32496
et al. , 2002	32501
et al.	32501
2002	32509
the host spinal cord tissue , viable transplanted Hoechst-prelabeled OEC/ONF	32532
the host spinal cord tissue	32532
viable transplanted Hoechst-prelabeled OEC/ONF	32561
those macrophages	32636
their blue fluorescence under UV illumination	32665
their blue fluorescence	32665
UV illumination	32695
addition	32715
a subpopulation of the transplanted Hoechst-prelabeled OEC/ONF	32725
a subpopulation	32725
the transplanted Hoechst-prelabeled OEC/ONF	32744
the p75-NGF receptor -LRB- Fig. 1D -RRB-	32811
the p75-NGF receptor	32811
Fig. 1D	32833
both transplanted and control animals	32846
both	32846
transplanted and control animals	32851
transplanted	32851
control animals	32868
small , but clearly visible cavities -LRB- with a diameter of about 100 μm -RRB-	32885
small , but clearly visible cavities	32885
a diameter of about 100 μm	32927
a diameter	32927
100 μm	32947
rostral and caudal	32975
the injury site	32997
a similar extent	33016
all animals , which may be the result of the injection procedure as they were located at approximately 1 mm rostral and caudal to the lesion gap	33036
all animals	33036
the result of the injection procedure	33062
the result	33062
the injection procedure	33076
they	33103
located at approximately 1 mm rostral and caudal	33113
approximately 1 mm	33124
the lesion gap	33165
no transplanted Hoechst-prelabeled OEC/ONF	33190
the OEC/ONF -- biomatrix complexes in the graft/lesion sites	33267
the OEC/ONF	33267
biomatrix complexes in the graft/lesion sites	33280
biomatrix complexes	33280
the graft/lesion sites	33303
a histological Hoechst staining	33327
the animals	33391
host cells	33426
the transplanted complexes	33451
it	33485
many host cells	33508
the biomatrix complexes -LRB- Fig. 1E -RRB-	33532
the biomatrix complexes	33532
Fig. 1E	33557
Additional immunostaining	33567
a subpopulation of these invading cells	33617
a subpopulation	33617
these invading cells	33636
them	33699
Schwann cells -LRB- Fig. 1F -RRB-	33719
Schwann cells	33719
Fig. 1F	33734
The identity of the rest of the invading cells	33744
The identity	33744
the rest of the invading cells	33760
the rest	33760
the invading cells	33772
Ingrowth of axons into the graft/lesion site	33808
Ingrowth	33808
axons into the graft/lesion site	33820
axons	33820
the graft/lesion site	33831
axon regrowth	33872
we	33894
axons	33928
the transplanted OEC/ONF -- biomatrix complex	33945
the transplanted OEC/ONF	33945
biomatrix complex	33971
we	33994
a general neurofilament -LRB- NF -RRB- staining	34017
NF	34042
control animals	34059
there	34076
an NF-positive fiber passing the GFAP-positive scar	34099
an NF-positive fiber	34099
the GFAP-positive scar	34128
NF-positive fiber growth into the lesion site	34161
NF-positive fiber growth	34161
the lesion site	34191
the outer circumferences of the lesion -LRB- i.e. at the border of the lesion gap -RRB-	34225
the outer circumferences	34225
the lesion -LRB- i.e. at the border of the lesion gap -RRB-	34253
the lesion	34253
i.e. at the border of the lesion gap	34265
i.e.	34265
the border of the lesion gap	34273
the border	34273
the lesion gap	34287
sharp contrast to this	34307
sharp contrast	34307
this	34325
numerous NF-positive fibers	34331
the OEC/ONF -- biomatrix complexes of transplanted animals -LRB- Fig. 3B -RRB-	34386
the OEC/ONF	34386
biomatrix complexes of transplanted animals -LRB- Fig. 3B -RRB-	34399
biomatrix complexes	34399
transplanted animals -LRB- Fig. 3B -RRB-	34422
transplanted animals	34422
Fig. 3B	34444
the DuraFilm	34468
the grafts	34490
a quantitative analysis	34508
the complex	34555
the lesion site	34602
we	34619
the ingrowth of NF-positive fibers -LRB- `` NF immunoreactivity occupation '' -RRB- in the complete lesion gap -LRB- irrespective of the degree in which the complex filled up this lesion gap -RRB-	34631
the ingrowth	34631
NF-positive fibers -LRB- `` NF immunoreactivity occupation '' -RRB- in the complete lesion gap -LRB- irrespective of the degree in which the complex filled up this lesion gap -RRB-	34647
NF-positive fibers -LRB- `` NF immunoreactivity occupation '' -RRB-	34647
NF-positive fibers	34647
NF	34668
immunoreactivity occupation ''	34671
immunoreactivity	34671
occupation ''	34688
the complete lesion gap	34704
irrespective of the degree in which the complex filled up this lesion gap	34729
irrespective	34729
the degree in which the complex filled up this lesion gap	34745
the degree	34745
the complex	34765
this lesion gap	34787
the GFAP-positive scar	34811
the graft/lesion site -LRB- Fig. 3A -RRB-	34847
the graft/lesion site	34847
Fig. 3A	34870
The size of the graft	34880
The size	34880
the graft	34892
lesion site , as demarcated by the GFAP-IR boundary ,	34903
lesion site	34903
the GFAP-IR boundary	34933
OEC/ONF-transplanted animals and control animals -LRB- data not shown -RRB-	34978
OEC/ONF-transplanted animals and control animals	34978
OEC/ONF-transplanted animals	34978
control animals	35011
data not shown	35028
data	35028
The occupation of the graft/lesion site by NF-positive fibers	35045
The occupation	35045
the graft/lesion site by NF-positive fibers	35063
the graft/lesion site	35063
NF-positive fibers	35088
0.41 ± 0.11 %	35111
0.41	35111
0.11 %	35118
transplanted animals versus 0.05 ± 0.02 % in control animals -LRB- Fig. 3C , P < 0.05 -RRB-	35127
transplanted animals	35127
0.05 ± 0.02 %	35155
0.05	35155
0.02 %	35162
control animals -LRB- Fig. 3C , P < 0.05 -RRB-	35171
control animals	35171
Fig. 3C , P < 0.05	35188
Fig. 3C , P <	35188
Fig. 3C	35188
P <	35197
P	35197
<	35199
0.05	35201
serotonin immunostaining	35217
serotonergic fibers in the intact spinal tissue -LRB- Fig. 3D -RRB-	35264
serotonergic fibers	35264
the intact spinal tissue -LRB- Fig. 3D -RRB-	35287
the intact spinal tissue	35287
Fig. 3D	35313
the graft / lesion site	35323
the graft	35323
lesion site	35334
serotonin-immunoreactive fibers -LRB- data not shown -RRB-	35371
serotonin-immunoreactive fibers	35371
data not shown	35404
data	35404
CS axon response BDA labeling of the CS tract	35421
CS axon response BDA	35421
the CS tract	35454
nine	35485
ten transplanted animals	35497
seven	35529
eight control animals	35542
BDA-labeled CS axons	35565
the graft/lesion site -LRB- Figs. 4A , C , D -RRB-	35620
the graft/lesion site	35620
Figs. 4A	35643
C	35653
D	35656
Most of these axons	35660
Most	35660
these axons	35668
the host/graft interface -LRB- Figs. 4A , C , D -RRB-	35708
the host/graft interface	35708
Figs. 4A	35734
C	35744
D	35747
No BDA-labeled CS axons	35751
the graft	35802
any of the animals	35815
any	35815
the animals	35822
a BDA-labeled CS axon	35849
the graft/lesion site	35895
one or two of the transplanted and control animals	35921
one or two of the transplanted	35921
one or two	35921
the transplanted	35935
control animals	35956
this	35973
the case caudal to the lesion site -LRB- Fig. 4E -RRB-	35987
the case	35987
the lesion site	36006
Fig. 4E	36023
The anterograde labeling efficiency	36033
the animals	36090
BDA immunoreactivity at the rostral reference	36103
BDA immunoreactivity	36103
the rostral reference	36127
12.3 % at maximum and 0.15 % at minimum	36153
12.3 % at maximum	36153
12.3 %	36153
maximum	36162
0.15 % at minimum	36174
0.15 %	36174
minimum	36183
No statistically significant differences in BDAlabeled CS axons	36192
No statistically significant differences	36192
BDAlabeled CS axons	36236
the two groups of animals	36277
the two groups	36277
animals	36295
These values	36304
the 100 % reference values with respect	36330
the 100 % reference values	36330
respect	36361
the BDA immunoreactivity occupation measures rostral , underneath , and caudal to the lesion	36372
the BDA immunoreactivity occupation measures rostral , underneath ,	36372
the BDA immunoreactivity occupation measures	36372
caudal to the lesion	36442
caudal	36442
the lesion	36452
Quantification of BDA immunoreactivity occupation at the four different locations and statistical testing usingANOVAR with Bonferroni	36464
Quantification	36464
BDA immunoreactivity occupation at the four different locations and statistical testing usingANOVAR with Bonferroni	36482
BDA immunoreactivity occupation at the four different locations	36482
BDA immunoreactivity occupation	36482
the four different locations	36517
statistical testing usingANOVAR with Bonferroni	36550
statistical testing usingANOVAR	36550
Bonferroni	36587
hoc	36603
there	36619
an overall difference in BDA immunoreactivity over the respective locations -LRB- Location : F1 ,14 = 504.85 , P < 0.001 -RRB-	36629
an overall difference	36629
BDA immunoreactivity	36654
the respective locations -LRB- Location : F1 ,14 = 504.85 , P < 0.001 -RRB-	36680
the respective locations	36680
Location : F1 ,14 = 504.85	36706
Location	36706
F1 ,14 = 504.85	36716
F1 ,14	36716
504.85	36724
P < 0.001	36732
P	36732
< 0.001	36734
<	36734
0.001	36736
Fig. 4B	36744
a reduction in BDA immunoreactivity -LRB- 1 -RRB- directly rostral to the lesion site , -LRB- 2 -RRB- underneath the lesion site , and -LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in both transplanted and control animals .	36758
a reduction	36758
BDA immunoreactivity -LRB- 1 -RRB- directly rostral to the lesion site , -LRB- 2 -RRB- underneath the lesion site , and -LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in both transplanted and control animals .	36773
BDA immunoreactivity -LRB- 1 -RRB-	36773
BDA immunoreactivity	36773
1	36795
rostral to the lesion site	36807
rostral	36807
the lesion site	36818
the lesion site , and -LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in both transplanted and control animals	36850
the lesion site , and -LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in	36850
the lesion site	36850
the lesion	36850
site	36861
-LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in	36871
caudal	36875
the lesion site as compared to the rostral reference in	36885
the lesion site	36885
the rostral reference in	36916
the rostral reference	36916
transplanted and control animals	36946
transplanted	36946
control animals	36963
addition	36983
an overall group difference	36993
Group : F1 ,14 = 12.09 , P < 0.01	37032
Group	37032
F1 ,14 = 12.09 , P < 0.01	37039
F1 ,14 = 12.09 , P <	37039
F1 ,14	37039
= 12.09 , P <	37045
12.09 , P	37047
12.09	37047
P	37054
0.01	37058
A significantly -LRB- P < 0.01 -RRB- higher BDA immunoreactivity was detected directly rostral to the lesion/graft site in transplanted animals -LRB- 65.0 ± 12.8 % -RRB- as compared to control animals -LRB- 13.1 ± 3.9 % -RRB- .	37065
A significantly -LRB- P < 0.01 -RRB-	37065
A significantly	37065
P < 0.01	37082
P	37082
< 0.01	37084
<	37084
0.01	37086
BDA immunoreactivity	37099
rostral to the lesion/graft site in transplanted animals -LRB- 65.0 ± 12.8 % -RRB- as compared to control animals -LRB- 13.1 ± 3.9 %	37142
rostral to the lesion/graft site in transplanted animals -LRB- 65.0 ± 12.8 % -RRB- as compared to control	37142
rostral to the lesion/graft site in transplanted	37142
rostral	37142
the lesion/graft site in transplanted	37153
the lesion/graft site	37153
transplanted	37178
animals -LRB- 65.0 ± 12.8 % -RRB- as compared to control	37191
animals -LRB- 65.0 ± 12.8 % -RRB-	37191
animals	37191
65.0 ± 12.8 %	37200
65.0	37200
12.8 %	37207
animals -LRB- 13.1 ± 3.9 %	37237
animals	37237
13.1 ± 3.9 %	37246
13.1	37246
3.9 %	37253
We	37260
the higher BDA immunoreactivity directly rostral to the injury site	37277
the higher BDA immunoreactivity	37277
the injury site	37329
a sprouting response by the injured CS axons , a reduction in CS axon die-back , or a combination of these two options	37359
a sprouting response by the injured CS axons	37359
a sprouting response	37359
the injured CS axons	37383
a reduction in CS axon die-back	37405
a reduction	37405
CS axon die-back	37420
a combination of these two options	37441
a combination	37441
these two options	37458
the CS axons approaching the host/graft interface	37502
the CS axons	37502
the host/graft interface	37527
axons	37567
a BDA/GAP43 double staining	37574
All the nine transplanted and seven control animals with a good BDA labeling of the CS tract staining were analyzed for GAP43 - positive BDA-immunoreactive axons .	37617
All the nine transplanted and seven control animals with a good BDA labeling of the CS tract staining were analyzed for GAP43	37617
All the	37617
nine transplanted and seven control animals with a good BDA labeling of the CS tract staining	37625
nine transplanted	37625
seven control animals with a good BDA labeling of the CS tract staining	37647
seven control animals	37647
a good BDA labeling of the CS tract staining	37674
a good BDA labeling	37674
the CS tract staining	37697
GAP43	37737
positive BDA-immunoreactive axons	37744
positive	37744
BDA-immunoreactive axons	37753
none of the transplanted or control animals	37782
none of the transplanted	37782
none	37782
the transplanted	37790
control animals	37810
we	37830
such axons -LRB- Fig. 4D -RRB- , suggesting that the transplantation effect on the injured CS axons rostral to the lesion site most likely involves a reduced die-back	37841
such axons -LRB- Fig. 4D -RRB-	37841
such axons	37841
Fig. 4D	37853
the transplantation effect on the injured CS axons rostral to the lesion site most likely	37879
the transplantation effect	37879
the injured CS axons rostral	37909
the lesion site most likely	37941
the lesion site	37941
a reduced die-back	37978
Functional outcome BBB locomotor rating scale The spinal cord injury	37998
Functional outcome BBB locomotor rating scale	37998
Functional outcome	37998
BBB locomotor rating scale	38017
The spinal cord injury	38044
functional impairment of the animals	38079
functional impairment	38079
the animals	38104
the first day after injury	38120
the first day	38120
injury	38140
the majority of animals	38148
the majority	38148
animals	38164
this study were not able to display plantar placement of their hind paws , although there was extensive movements of the hip , the knee , and the ankle	38186
this study	38186
plantar placement of their hind paws	38222
plantar placement	38222
their hind paws	38243
there	38269
extensive movements of the hip , the knee , and the ankle	38279
extensive movements	38279
the hip , the knee , and the ankle	38302
the hip	38302
the knee	38311
the ankle	38325
the first week after injury	38339
the first week	38339
injury	38360
all the animals	38368
plantar placement of the hind paws , many with weight support	38388
plantar placement	38388
the hind paws	38409
weight support	38434
3 weeks after injury	38453
3 weeks	38453
injury	38467
all the animals	38475
consistent weight	38498
plantar	38526
BBB score 11	38544
BBB	38544
score 11	38548
some of them	38563
some	38563
them	38571
occasional coordination	38586
the forelimbs and the hind limbs -LRB- BBB score 12 -RRB-	38618
the forelimbs	38618
the hind limbs -LRB- BBB score 12 -RRB-	38636
the hind limbs	38636
BBB score 12	38652
the 9 weeks post-injury	38678
9 weeks	38682
the animals	38703
the BBB locomotor test on a weekly basis	38732
the BBB locomotor test	38732
a weekly basis	38758
No difference	38774
BBB scores observed between transplanted and control animals at any time point -LRB- Fig. 5A -RRB-	38795
BBB scores	38795
transplanted and control animals at any time point -LRB- Fig. 5A -RRB-	38823
transplanted and control animals	38823
any time point -LRB- Fig. 5A -RRB-	38859
any time point	38859
Fig. 5A	38875
most of the animals in both groups	38894
most	38894
the animals in both groups	38902
the animals	38902
both groups	38917
a BBB score of 11	38941
a BBB score	38941
11	38956
the third week	38964
the ninth week	38982
A BBB score of 11	38998
A BBB score	38998
11	39013
frequent to consistent weight	39025
plantar stepping without coordination -LRB- Basso et al. , 1995 -RRB-	39065
plantar	39065
coordination -LRB- Basso et al. , 1995 -RRB-	39090
coordination	39090
Basso	39104
et al. , 1995	39110
et al.	39110
1995	39118
CatWalk-based BBB scale	39125
the CatWalk gait analysis	39152
the RI	39179
an objective measure of coordination	39205
an objective measure	39205
coordination	39229
the CatWalk-based coordination data	39248
the BBB scores	39304
3 , 6 , and 9 weeks	39322
3	39322
6	39325
9 weeks	39332
injury	39346
the BBB scores	39354
Fig. 5B	39398
animals	39421
their BBB scores	39439
from 11.4 -LRB- DPO21 -RRB- , 11.8 -LRB- DPO42 -RRB- ,	39456
from 11.4 -LRB- DPO21 -RRB-	39456
from 11.4	39456
DPO21	39467
11.8 -LRB- DPO42 -RRB-	39475
and 11.4 -LRB- DPO63 -RRB-	39489
and 11.4	39489
DPO63	39499
15.2 -LRB- DPO21 -RRB- , 15.3 -LRB- DPO42 -RRB- , and 15.8 -LRB- DPO63 -RRB-	39509
15.2 -LRB- DPO21 -RRB-	39509
15.3 -LRB- DPO42 -RRB-	39523
15.8 -LRB- DPO63 -RRB-	39541
all statistically significant using a Student 's t test -LRB- P < 0.01 -RRB-	39555
all statistically significant	39555
a Student 's t test	39591
a Student 's	39591
P < 0.01	39611
P	39611
< 0.01	39613
<	39613
0.01	39615
control animals	39635
their BBB scores	39661
integration of the CatWalk-based coordination data : from 11.1 -LRB- DPO21 -RRB- , 11.8 -LRB- DPO42 -RRB- , and 11.6 -LRB- DPO63 -RRB- to 15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB- ;	39683
integration	39683
the CatWalk-based coordination data : from 11.1 -LRB- DPO21 -RRB- , 11.8 -LRB- DPO42 -RRB- , and 11.6 -LRB- DPO63 -RRB- to 15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB- ;	39698
the CatWalk-based coordination data	39698
11.1 -LRB- DPO21 -RRB- , 11.8 -LRB- DPO42 -RRB- , and 11.6 -LRB- DPO63 -RRB- to 15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB-	39740
11.1 -LRB- DPO21 -RRB-	39740
11.8 -LRB- DPO42 -RRB-	39754
11.6 -LRB- DPO63 -RRB- to 15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB-	39772
11.6 -LRB- DPO63 -RRB-	39772
15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB-	39788
15.4 -LRB- DPO21 -RRB-	39788
14.6 -LRB- DPO42 -RRB-	39802
13.6 -LRB- DPO63 -RRB-	39820
DPO63	39845
all these time points	39852
a Student 's t test -LRB- P < 0.01 -RRB-	39910
a Student 's t test	39910
a Student 's	39910
P < 0.01	39930
P	39930
< 0.01	39932
<	39932
0.01	39934
the BBB scores increased to a similar extent in both the transplanted and control animals	39947
the BBB scores increased to a similar extent in both the transplanted	39947
the BBB scores	39947
a similar extent	39975
the transplanted	40000
control animals	40021
no significant difference	40038
the two groups	40087
integration of the CatWalk-based coordination data	40107
integration	40107
the CatWalk-based coordination data	40122
the BBB scores at any time point -LRB- Fig. 5B -RRB-	40163
the BBB scores	40163
any time point -LRB- Fig. 5B -RRB-	40181
any time point	40181
Fig. 5B	40197
CatWalk gait analysis Duration of walkway	40207
CatWalk gait analysis Duration	40207
walkway	40241
respect	40263
the CatWalk gait analysis	40274
it	40301
the duration of walkway crossing	40330
the duration	40330
walkway crossing	40346
walkway	40346
an influence on the locomotion of the animals -LRB- Koopmans et al. , 2005 -RRB-	40372
an influence	40372
the locomotion of the animals -LRB- Koopmans et al. , 2005 -RRB-	40388
the locomotion	40388
the animals -LRB- Koopmans et al. , 2005 -RRB-	40406
the animals	40406
Koopmans	40419
et al. , 2005	40428
et al.	40428
2005	40436
it	40454
identical durations of walkway crossing in both animal groups when comparing the various locomotor parameters	40475
identical durations	40475
walkway crossing in both animal groups when comparing the various locomotor parameters	40498
walkway	40498
animal groups	40523
the various locomotor parameters	40552
Preoperative training on the CatWalk	40586
Preoperative training	40586
the CatWalk	40611
rapid runway crossings of 1.39 ± 0.07 s and 1.47 ± 0.06 s	40635
rapid runway crossings	40635
1.39 ± 0.07 s and 1.47 ± 0.06 s	40661
1.39 ± 0.07 s	40661
1.39 ±	40661
0.07 s	40668
1.47 ± 0.06 s	40679
1.47	40679
0.06 s	40686
transplanted and control animals , respectively	40696
transplanted	40696
control animals , respectively	40713
control animals	40713
Three weeks	40744
injury	40762
the runway crossing	40770
the runway	40770
significantly to 2.11 ± 0.12 s and 2.45 ± 0.25 s	40800
significantly to 2.11 ± 0.12 s	40800
2.11 ± 0.12	40817
2.11 ±	40817
0.12	40824
2.45 ± 0.25 s	40835
2.45 ±	40835
0.25 s	40842
transplanted and control animals , respectively	40852
transplanted	40852
control animals , respectively	40869
control animals	40869
the 6 and 9 weeks postinjury time points	40903
6	40907
9 weeks	40913
there	40945
no further increase in runway crossing in both animal groups	40955
no further increase	40955
runway crossing in both animal groups	40978
runway	40978
animal groups	41002
A statistically significant increase in crossing time between the preoperative and postinjury time points in both animal groups	41017
A statistically significant increase	41017
time between the preoperative and postinjury time points	41066
time	41066
the preoperative and postinjury time points	41079
both animal groups	41126
Time : F3 ,39 = 7.37 , P < 0.001 ; and F3 ,31	41156
Time	41156
F3 ,39 = 7.37 , P < 0.001	41162
F3 ,39 = 7.37 , P <	41162
F3 ,39	41162
= 7.37 , P <	41168
7.37 , P	41170
7.37	41170
P	41176
0.001	41180
F3 ,31	41191
4.71	41199
P < 0.01 ; 1-way	41205
P	41205
< 0.01 ; 1-way	41207
<	41207
0.01 ; 1-way	41209
ANOVA/Bonferroni	41221
hoc over four time points for transplanted and control animals , respectively	41243
hoc	41243
four time points for transplanted and control animals , respectively	41252
four time points	41252
transplanted and control animals , respectively	41273
transplanted	41273
control animals , respectively	41290
control animals	41290
no statistically significant difference in crossing time	41349
no statistically significant difference	41349
time	41401
the two animal groups	41424
any of the four time points	41449
any	41449
the four time points	41456
a legitimate comparison of data between the two groups	41489
a legitimate comparison	41489
data between the two groups	41516
data	41516
the two groups	41529
any given time point	41559
Stride length of hind limbs The stride length of the hind limbs	41581
Stride length	41581
hind limbs The stride length of the hind limbs	41598
hind limbs	41598
The stride length of the hind limbs	41609
The stride length	41609
the hind limbs	41630
the distance between the print of one hind paw in one step cycle to the print of the same hind paw in the next step cycle	41648
the distance	41648
the print of one hind paw in one step cycle to the print of the same hind paw in the next step cycle	41669
the print	41669
one hind paw in one step cycle to the print of the same hind paw in the next step cycle	41682
one hind paw	41682
one step cycle to the print of the same hind paw in the next step cycle	41698
one step cycle	41698
the print of the same hind paw in the next step cycle	41716
the print	41716
the same hind paw in the next step cycle	41729
the same hind paw	41729
the next step cycle	41750
injury	41778
the stride length of transplanted and control animals	41786
the stride length	41786
transplanted and control animals	41807
transplanted	41807
control animals	41824
148.1 ± 2.8 mm and 140.2 ± 2.6 mm , respectively -LRB- n.s. ; Fig. 5C -RRB-	41844
148.1 ± 2.8 mm and 140.2 ± 2.6 mm , respectively	41844
148.1 ± 2.8 mm	41844
148.1 ±	41844
2.8 mm	41852
140.2 ± 2.6 mm , respectively	41863
140.2 ±	41863
2.6 mm	41871
n.s. ; Fig. 5C	41893
n.s.	41893
Fig. 5C	41899
the four different time points	41914
there	41946
a statistically significant decrease -LRB- Time : F1 ,16 = 18.14 , P < 0.01 -RRB-	41956
a statistically significant decrease	41956
Time : F1 ,16 = 18.14	41994
Time	41994
F1 ,16 = 18.14	42000
F1 ,16	42000
18.14	42008
P < 0.01	42015
P	42015
< 0.01	42017
<	42017
0.01	42019
an overall significant difference	42039
the two groups -LRB- Group : F1 ,16 = 6.11 , P < 0.05 -RRB-	42094
the two groups	42094
Group : F1 ,16 = 6.11	42110
Group	42110
F1 ,16 = 6.11	42117
F1 ,16	42117
= 6.11	42123
P < 0.05	42131
P	42131
< 0.05	42133
<	42133
0.05	42135
the last time point in this study -LRB- i.e. 9 weeks post-injury -RRB-	42145
the last time point	42145
this study -LRB- i.e. 9 weeks post-injury -RRB-	42168
this study	42168
9 weeks	42185
Student 's t testing	42207
Student 's	42207
the stride length of the hind limbs in transplanted animals	42239
the stride length	42239
the hind limbs in transplanted animals	42260
the hind limbs	42260
transplanted animals	42278
control animals	42332
134.5 ± 3.1 mm and 122.5 ± 3.3 mm , respectively ; P < 0.05 ; Fig. 5C	42349
134.5 ± 3.1 mm	42349
134.5 ±	42349
3.1 mm	42357
122.5 ± 3.3 mm , respectively ; P < 0.05 ; Fig. 5C	42368
122.5 ± 3.3 mm , respectively	42368
122.5 ±	42368
3.3 mm	42376
P < 0.05	42398
P <	42398
P	42398
0.05	42402
Fig. 5C	42408
Fig.	42408
5C	42413
speed of hind limbs	42424
speed	42424
hind limbs	42433
This parameter	42444
the distance -LRB- stride length -RRB- that the hind paw crosses	42468
the distance -LRB- stride length -RRB-	42468
the distance	42468
stride length	42482
the hind paw crosses	42502
one step cycle and the time -LRB- swing duration -RRB- it takes	42530
one step cycle	42530
the time -LRB- swing duration -RRB- it takes	42549
the time	42549
swing duration	42559
it	42575
injury	42592
the swing speed of the hind limbs	42600
the swing speed	42600
the hind limbs	42619
1.20 ± 0.05 m/s and 1.15 ± 0.02 m/s for transplanted and control animals , respectively -LRB- n.s. -RRB-	42638
1.20 ± 0.05 m/s	42638
1.20	42638
0.05 m/s	42645
1.15 ± 0.02 m/s for transplanted and control animals , respectively -LRB- n.s. -RRB-	42658
1.15 ± 0.02 m/s	42658
transplanted and control animals , respectively -LRB- n.s. -RRB-	42678
transplanted	42678
control animals , respectively -LRB- n.s. -RRB-	42695
control animals , respectively	42695
control animals	42695
n.s.	42726
a tendency	42742
a difference between the two animal groups -LRB- Group : F1 ,16 = 4.34 , P = 0.054 -RRB-	42770
a difference	42770
the two animal groups -LRB- Group : F1 ,16 = 4.34 , P = 0.054 -RRB-	42791
the two animal groups	42791
Group : F1 ,16 = 4.34 , P = 0.054	42814
Group	42814
F1 ,16 = 4.34 , P = 0.054	42821
F1 ,16 = 4.34	42821
F1 ,16	42821
4.34	42829
P = 0.054	42835
P	42835
0.054	42839
all time points	42852
there	42869
a significant change in swing speed -LRB- Time : F1 ,16 = 9.47 , P < 0.01 -RRB-	42879
a significant change	42879
swing speed -LRB- Time : F1 ,16 = 9.47 , P < 0.01 -RRB-	42903
swing speed	42903
Time : F1 ,16 = 9.47	42916
Time	42916
F1 ,16 = 9.47	42922
F1 ,16	42922
9.47	42930
P < 0.01	42936
P	42936
< 0.01	42938
<	42938
0.01	42940
Student 's t tests	42947
Student 's	42947
the swing speed of the hind limbs	42977
the swing speed	42977
the hind limbs	42996
transplanted animal	43039
animals	43082
the end of the experiment -LRB- i.e. 9 weeks after injury -RRB- -LRB- Fig. 5D ; P < 0.05 -RRB-	43093
the end	43093
the experiment -LRB- i.e. 9 weeks after injury -RRB- -LRB- Fig. 5D ; P < 0.05 -RRB-	43104
the experiment -LRB- i.e. 9 weeks after injury -RRB-	43104
the experiment	43104
i.e. 9 weeks after injury	43120
i.e.	43120
9 weeks after injury	43125
9 weeks	43125
injury	43139
Fig. 5D ; P < 0.05	43148
Fig. 5D	43148
P < 0.05	43157
P <	43157
P	43157
0.05	43161
inter-group changes	43177
both stride length of the hind limbs	43212
both stride length	43212
the hind limbs	43234
speed of the hind limbs	43259
speed	43259
the hind limbs	43268
there	43284
no change in swing duration between the two animal groups -LRB- data not shown -RRB-	43294
no change	43294
swing duration between the two animal groups -LRB- data not shown -RRB-	43307
swing duration	43307
the two animal groups	43330
data not shown	43353
data	43353
Discussion	43370
We	43381
the effect of a multifactorial acute transplantation strategy on axon regrowth	43392
the effect	43392
a multifactorial acute transplantation strategy on axon regrowth	43406
a multifactorial acute transplantation strategy	43406
axon regrowth	43457
large spinal lesion gaps	43478
This strategy	43504
an OEC/ONF continuum	43537
the injured spinal cord involved two aspects : an aligned OEC/ONF -- biomatrix complex to bridge a 2-mm dorsal hemisection lesion site and additional OEC/ONF cell injections at 1 mm rostral and 1 mm caudal to the injury site -LRB- Fig. 2 -RRB-	43561
the injured spinal cord	43561
two aspects	43594
an aligned OEC/ONF -- biomatrix complex to bridge a 2-mm dorsal hemisection lesion site and additional OEC/ONF cell injections at 1 mm rostral and 1 mm caudal to the injury site -LRB- Fig. 2 -RRB-	43607
an aligned OEC/ONF	43607
biomatrix complex to bridge a 2-mm dorsal hemisection lesion site and additional OEC/ONF cell injections at 1 mm rostral and 1 mm caudal to the injury site -LRB- Fig. 2 -RRB-	43626
biomatrix complex	43626
a 2-mm dorsal hemisection lesion site and additional OEC/ONF cell injections	43654
a 2-mm dorsal hemisection lesion site	43654
additional OEC/ONF cell injections	43696
1 mm rostral and 1 mm caudal	43734
1 mm rostral	43734
1 mm caudal	43751
the injury site	43766
Fig. 2	43783
We	43792
the transplanted OEC/ONF	43805
the injection areas	43842
the biomatrices	43874
the lesion gaps	43897
the surviving OEC/ONF in the injection areas	43927
the surviving OEC/ONF	43927
the injection areas	43952
these areas	43993
an OEC/ONF continuum	44013
we	44064
our transplantation strategy	44085
numerous axons	44125
the OEC/ONF -- biomatrix complex	44153
the OEC/ONF	44153
biomatrix complex	44165
None of these axons	44184
None	44184
these axons	44192
CS or raphespinal origin	44211
CS	44211
raphespinal origin	44217
BDA-labeled CS axons	44246
the graft	44281
any of the animals	44294
any	44294
the animals	44301
the transplantation strategy	44314
a clear increase of injured BDA-labeled CS axons	44355
a clear increase	44355
injured BDA-labeled CS axons	44375
the injury site	44424
This response of injured BDA-labeled CS axons	44441
This response	44441
injured BDA-labeled CS axons	44458
a reduced die-back of the axons as a result of the transplantation intervention	44499
a reduced die-back	44499
the axons as a result of the transplantation intervention	44521
the axons	44521
a result of the transplantation intervention	44534
a result	44534
the transplantation intervention	44546
none of these CS axons	44585
none	44585
these CS axons	44593
GAP43/B50 - positive	44612
GAP43/B50	44612
addition	44636
the transplantation strategy used	44646
the transplantation strategy	44646
a recovery	44691
stride length	44705
speed of the hind limbs	44729
speed	44729
the hind limbs	44738
OEC vs. OEC/ONF Currently	44754
OEC	44754
OEC/ONF Currently	44762
there	44781
an ongoing discussion about the optimal composition of olfactory ensheathing cell cultures to be used for stimulating regeneration of axons severed by an experimental spinal cord injury -LRB- Barnett and Chang , 2004 -RRB-	44790
an ongoing discussion	44790
the optimal composition of olfactory ensheathing cell cultures	44818
the optimal composition	44818
olfactory ensheathing cell cultures	44845
regeneration of axons severed by an experimental spinal cord injury -LRB- Barnett and Chang , 2004 -RRB-	44908
regeneration	44908
axons severed by an experimental spinal cord injury -LRB- Barnett and Chang , 2004 -RRB-	44924
axons	44924
an experimental spinal cord injury -LRB- Barnett and Chang , 2004 -RRB-	44941
an experimental spinal cord injury	44941
Barnett and Chang	44977
2004	44996
Acute transplantation of mixed OEC/ONF cultures	45003
Acute transplantation	45003
mixed OEC/ONF cultures	45028
regrowth of injured CS axons	45066
regrowth	45066
injured CS axons	45078
relatively small spinal lesion gaps -LRB- Li et al. , 1997 , 1998 -RRB-	45102
relatively small spinal lesion gaps	45102
Li	45139
et al. , 1997 , 1998	45142
et al.	45142
1997	45150
1998	45156
purified OEC cultures	45177
complete or incomplete transection sites , injured	45222
complete or incomplete transection sites	45222
CS axons	45272
the relatively small lesion gaps -LRB- Ramon-Cueto et al. , 2000 ; Nash et al. , 2002 -RRB-	45309
the relatively small lesion gaps	45309
Ramon-Cueto	45343
et al. , 2000 ; Nash et al. , 2002	45355
et al.	45355
2000 ; Nash et al.	45363
2000	45363
Nash et al.	45369
Nash	45369
et al.	45374
2002	45382
these small lesion gaps	45423
CS axons	45456
the spinal cord surface	45501
the presence of meningeal fibroblasts -LRB- Ramon - Cueto et al. , 2000 -RRB-	45528
the presence	45528
meningeal fibroblasts -LRB- Ramon - Cueto et al. , 2000 -RRB-	45544
meningeal fibroblasts	45544
Ramon	45567
Cueto et al. , 2000	45574
Cueto	45574
et al.	45580
2000	45588
This	45595
a cooperation of the transplanted OEC with fibroblasts	45609
a cooperation	45609
the transplanted OEC with fibroblasts	45626
the transplanted OEC	45626
fibroblasts	45652
contrast to small spinal lesion gaps	45668
contrast	45668
small spinal lesion gaps	45680
large spinal lesion gaps	45706
long-distance axon regrowth	45739
Acute transplantation of purified OEC cultures	45768
Acute transplantation	45768
purified OEC cultures	45793
very few injured CS axons	45830
around large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	45866
around large spinal lesion gaps	45866
Chuah	45899
et al. , 2004	45905
et al.	45905
2004	45913
it	45930
OEC and ONF	45950
long-distance olfactory axon regeneration -LRB- Li et al. , 2005 -RRB-	45978
long-distance olfactory axon regeneration	45978
Li	46021
et al. , 2005	46024
et al.	46024
2005	46032
our multifactorial transplantation strategy in the spinal cord , transplanted OEC	46051
our multifactorial transplantation strategy	46051
the spinal cord , transplanted OEC	46098
the spinal cord	46098
OEC	46128
ONF	46133
long-distance regrowth of injured CS axons	46164
long-distance regrowth	46164
injured CS axons	46190
Multifactorial transplantation strategy and regrowth	46208
injured CS axons across large spinal gaps	46264
injured CS axons	46264
large spinal gaps	46288
repair of large spinal lesion gaps	46336
repair	46336
large spinal lesion gaps	46346
The long-distance axon regrowth , required in large spinal lesion gaps ,	46398
The long-distance axon regrowth	46398
large spinal lesion gaps	46443
influence	46476
at least three issues	46489
a continuum of growth-promoting cells within the spinal cord	46519
a continuum	46519
growth-promoting cells within the spinal cord	46534
growth-promoting cells	46534
the spinal cord	46564
CS axons	46589
grafts composed of immature astrocytes in a collagen matrix but did not re-enter the caudal host	46624
grafts	46624
immature astrocytes in a collagen matrix	46643
immature astrocytes	46643
a collagen matrix	46666
the caudal host	46705
spinal cord -LRB- Joosten et al. , 2004 -RRB-	46721
spinal cord	46721
Joosten	46734
et al. , 2004	46742
et al.	46742
2004	46750
It	46757
this lack of CS axon re-entry into the host tissue	46779
this lack	46779
CS axon re-entry into the host tissue	46792
CS axon re-entry	46792
the host tissue	46814
the absence of transplanted cells in the host tissue	46848
the absence	46848
transplanted cells in the host tissue	46863
transplanted cells	46863
the host tissue	46885
the alignment of cells	46910
the alignment	46910
cells	46927
the large lesion gaps	46951
A specific organization of astrocytes	46974
A specific organization	46974
astrocytes	47001
utmost importance for the correct long-distance outgrowth of the CS tract	47039
utmost importance	47039
the correct long-distance outgrowth of the CS tract	47061
the correct long-distance outgrowth	47061
the CS tract	47100
development -LRB- Joosten and Gribnau , 1989 -RRB-	47120
development	47120
Joosten and Gribnau	47133
1989	47154
a clear orientation of transplanted OEC	47174
a clear orientation	47174
transplanted OEC	47197
directional host axon growth from the thalamus	47229
directional host axon growth	47229
the thalamus	47263
the hippocampus -LRB- Perez-Bouza et al. , 1998 -RRB-	47279
the hippocampus	47279
Perez-Bouza	47296
et al. , 1998	47308
et al.	47308
1998	47316
Third	47323
OEC and ONF	47336
long-distance olfactory axon regeneration -LRB- Li et al. , 2005 -RRB-	47358
long-distance olfactory axon regeneration	47358
Li	47401
et al. , 2005	47404
et al.	47404
2005	47412
the use of these mixed cultures	47419
the use	47419
these mixed cultures	47430
long-distance regrowth of axons severed by an SCI	47487
long-distance regrowth	47487
axons severed by an SCI	47513
axons	47513
an SCI	47530
our multifactorial transplantation strategy	47541
all these three issues	47586
all these	47586
three issues	47596
OEC/ONF	47632
transplanted both into the 2-mm dorsal hemisection lesion gap -LRB- cultured on biomatrices -RRB- and into the rostral and caudal host tissue	47645
transplanted	47645
the 2-mm dorsal hemisection lesion gap	47668
biomatrices	47720
the rostral and caudal host	47742
the rostral	47742
caudal host	47758
tissue	47770
Putative migration of OEC/ONF within the injured spinal cord , as described previously -LRB- Li et al. , 1998 -RRB-	47778
Putative migration	47778
OEC/ONF within the injured spinal cord , as described previously -LRB- Li et al. , 1998 -RRB-	47800
OEC/ONF	47800
the injured spinal cord , as described previously	47815
the injured spinal cord	47815
Li	47865
et al. , 1998	47868
et al.	47868
1998	47876
an OEC/ONF continuum	47899
OEC/ONF -- biomatrix complexes , which are known to stimulate directional neurite outgrowth in vitro -LRB- Deumens et al. , 2004 -RRB-	47937
OEC/ONF -- biomatrix complexes , which are known to stimulate directional neurite outgrowth in vitro	47937
OEC/ONF	47937
biomatrix complexes , which are known to stimulate directional neurite outgrowth in vitro	47946
biomatrix complexes	47946
directional neurite outgrowth	47996
Deumens	48036
et al. , 2004	48044
et al.	48044
2004	48052
the lesion gaps	48082
Third , mixed OEC/ONF cultures	48099
Third	48099
mixed OEC/ONF cultures	48106
Our multifactorial transplantation intervention	48140
two main histological outcomes	48201
there	48240
an enhanced presence of injured CS axons directly rostral to the spinal lesion gap -LRB- Fig. 4 -RRB-	48250
an enhanced presence	48250
injured CS axons directly rostral to the spinal lesion gap -LRB- Fig. 4 -RRB-	48274
injured CS axons	48274
the spinal lesion gap -LRB- Fig. 4 -RRB-	48311
the spinal lesion gap	48311
Fig. 4	48334
numerous axon	48351
the OEC / ONF --	48376
the OEC	48376
ONF	48385
biomatrix complexes in the spinal lesion gaps -LRB- Fig. 3 -RRB-	48389
biomatrix complexes	48389
the spinal lesion gaps -LRB- Fig. 3 -RRB-	48412
the spinal lesion gaps	48412
Fig. 3	48436
these axons	48460
an aligned phenotype	48487
The enhanced presence of CS axons	48509
The enhanced presence	48509
CS axons	48534
the lesion gap may reflect a reduced die-back of injured CS axons because the injured CS axons were immunonegative for GAP43/B50	48563
the lesion gap	48563
a reduced die-back of injured CS axons	48590
a reduced die-back	48590
injured CS axons	48612
the injured CS axons	48637
GAP43/B50	48682
Die-back of injured CS axons	48693
Die-back	48693
injured CS axons	48705
injury	48753
the majority of CS axons	48772
the majority	48772
CS axons	48788
between 1 and 2.5 mm rostral	48811
the injury site at 8 -- 10 weeks after trauma -LRB- Pallini et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999 -RRB-	48843
the injury site at 8 -- 10 weeks after trauma	48843
the injury site at 8	48843
the injury site	48843
8	48862
10 weeks after trauma	48864
10 weeks	48864
trauma	48879
Pallini et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	48887
Pallini	48887
et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	48895
et al. , 1988	48895
et al.	48895
1988	48903
von Meyenburg et al. , 1998	48909
von Meyenburg	48909
et al. , 1998	48923
et al.	48923
1998	48931
Oudega et al. , 1999	48937
Oudega	48937
et al. , 1999	48944
et al.	48944
1999	48952
Our results	48959
sharp contrast	48978
those obtained after transplanting mixed OEC/ONF cultures in small spinal lesion gaps , thereby stimulating regrowth of CS axons through the spinal lesion sites and into the caudal spinal tissue up to 1 cm -LRB- Li et al. , 1997 , 1998 -RRB-	48996
those	48996
mixed OEC/ONF cultures	49031
small spinal lesion gaps	49057
regrowth of CS axons through the spinal lesion sites and into the caudal spinal tissue up to 1 cm -LRB- Li et al. , 1997 , 1998 -RRB-	49103
regrowth	49103
CS axons through the spinal lesion sites and into the caudal spinal tissue up to 1 cm -LRB- Li et al. , 1997 , 1998 -RRB-	49115
CS axons	49115
the spinal lesion sites	49132
the caudal spinal tissue	49165
up to 1 cm -LRB- Li et al. , 1997 , 1998 -RRB-	49190
up to 1 cm	49190
Li	49202
et al. , 1997 , 1998	49205
et al.	49205
1997	49213
1998	49219
We	49226
three possibilities involved in the contrasting results	49237
three possibilities	49237
the contrasting results	49269
OEC/ONF transplants	49301
small lesion gaps -LRB- Li et al. , 1997 , 1998 , 2003 -RRB-	49341
small lesion gaps	49341
Li	49360
et al. , 1997 , 1998 , 2003	49363
et al.	49363
1997	49371
1998	49377
2003	49383
our study	49393
no Hoechst-prelabeled OEC/ONF	49404
the OEC/ONF -- biomatrix complexes transplanted into the large lesion gap -LRB- see below -RRB-	49451
the OEC/ONF	49451
biomatrix complexes transplanted into the large lesion gap -LRB- see below -RRB-	49463
biomatrix complexes	49463
the large lesion gap -LRB- see below -RRB-	49501
the large lesion gap	49501
the lesion model of Li and co-workers	49543
the lesion model	49543
Li and co-workers	49563
Li	49563
co-workers	49570
ours	49604
The level of the lesion	49610
The level	49610
the lesion	49623
i.e. high cervical vs. low thoracic	49644
i.e.	49644
low thoracic	49667
The capacity of an injured axon to regrow	49681
The capacity	49681
an injured axon to regrow	49697
an increasing distance between the injury and the soma of the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49741
an increasing distance	49741
the injury and the soma of the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49772
the injury	49772
the soma of the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49787
the soma	49787
the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49799
the injured neuron	49799
Richardson	49819
et al. , 1984	49830
et al.	49830
1984	49838
this	49853
the extent of the lesion	49859
the extent	49859
the lesion	49873
i.e.	49894
lesion of the CS tract vs. 2 - mm-wide dorsal hemisection injury	49907
lesion of the CS tract	49907
lesion	49907
the CS tract	49917
2 - mm-wide dorsal hemisection injury	49934
injured CS axons	49981
small spinal lesion gaps	50016
one-way approaches such as simply injecting OEC/ONF suspensions -LRB- Li et al. , 1998 -RRB-	50047
one-way approaches	50047
OEC/ONF suspensions -LRB- Li et al. , 1998 -RRB-	50091
OEC/ONF suspensions	50091
Li	50112
et al. , 1998	50115
et al.	50115
1998	50123
long distance of injured CS axons across large lesion gaps	50130
long distance	50130
injured CS axons across large lesion gaps	50147
injured CS axons	50147
large lesion gaps	50171
additional interventions , such as the use of growth-promoting bridges	50201
additional interventions	50201
the use of growth-promoting bridges	50235
the use	50235
growth-promoting bridges	50246
these large lesion gaps	50278
such bridges	50312
growth-promoting cells and biodegradable matrices	50340
growth-promoting cells	50340
biodegradable matrices	50367
our study	50391
some disadvantages of the specific combination of OEC/ONF with poly -LRB- D , L -RRB- - lactide matrices like a lack of OEC/ONF survival on the matrices within the lesion site and a poor integration of the complexes into the host spinal tissue	50415
some disadvantages	50415
the specific combination of OEC/ONF with poly -LRB- D , L -RRB- - lactide matrices like a lack of OEC/ONF survival on the matrices within the lesion site and a poor integration of the complexes into the host spinal tissue	50437
the specific combination	50437
OEC/ONF with poly -LRB- D , L -RRB- - lactide matrices like a lack of OEC/ONF survival on the matrices within the lesion site and a poor integration of the complexes into the host spinal tissue	50465
OEC/ONF with poly -LRB- D , L -RRB- - lactide matrices like a lack of OEC/ONF survival on the matrices within the lesion site	50465
OEC/ONF with poly -LRB- D , L -RRB-	50465
OEC/ONF	50465
poly -LRB- D , L -RRB-	50478
poly	50478
lactide matrices like a lack of OEC/ONF survival on the matrices within the lesion site	50488
lactide matrices	50488
a lack of OEC/ONF survival on the matrices within the lesion site	50510
a lack	50510
OEC/ONF survival on the matrices within the lesion site	50520
OEC/ONF survival	50520
the matrices within the lesion site	50540
the matrices	50540
the lesion site	50560
a poor integration of the complexes into the host spinal tissue	50580
a poor integration	50580
the complexes into the host spinal tissue	50602
the complexes	50602
the host spinal tissue	50621
Third , CS axon regrowth across a 2-mm-long lesion gap and into the caudal host tissue	50662
Third	50662
CS axon regrowth across a 2-mm-long lesion gap and into the caudal host tissue	50669
CS axon regrowth	50669
a 2-mm-long lesion gap	50693
the caudal host tissue	50725
more than the 9 weeks	50760
A 9-week period	50783
CS axon regrowth	50829
relatively small lesions -LRB- Li et al. , 1998 -RRB-	50853
relatively small lesions	50853
Li	50879
et al. , 1998	50882
et al.	50882
1998	50890
our data , showing CS axons present almost exclusively rostral to the injury site ,	50906
our data	50906
CS axons	50924
present almost exclusively rostral to the injury site	50933
the injury	50971
the time after injury	51001
the time	51001
injury	51016
the determining factor in the CS axon regrowth response	51030
the determining factor	51030
the CS axon regrowth response	51056
inter-group differences in CS axon regrowth	51096
inter-group differences	51096
CS axon regrowth	51123
rostral	51165
the injury site	51176
both OEC/ONF-transplanted animals and untreated control animals	51196
OEC/ONF-transplanted animals	51201
a few CS axons	51261
the gray matter underneath the lesion site	51293
the gray matter	51293
the lesion site	51320
the gray matter of the caudal spinal tissue	51347
the gray matter	51347
the caudal spinal tissue	51366
line with this	51395
line	51395
this	51405
others	51411
a similar CS axon regrowth response	51424
OEC transplantation	51466
large lesion gaps associated with thoracic dorsal column transection -LRB- Chuah et al. , 2004 -RRB-	51491
large lesion gaps	51491
thoracic dorsal column transection -LRB- Chuah et al. , 2004 -RRB-	51525
thoracic dorsal column transection	51525
Chuah	51561
et al. , 2004	51567
et al.	51567
2004	51575
NF-positive axon growth into the lesion site	51593
NF-positive axon growth	51593
the lesion site	51622
we	51639
a spontaneous response of endogenous tissue repair	51660
a spontaneous response	51660
endogenous tissue repair	51686
dorsal hemisection injury of the thoracic spinal cord of the rat -LRB- Brook et al. , 2000 -RRB-	51717
dorsal hemisection injury	51717
the thoracic spinal cord of the rat -LRB- Brook et al. , 2000 -RRB-	51746
the thoracic spinal cord	51746
the rat -LRB- Brook et al. , 2000 -RRB-	51774
the rat	51774
Brook	51783
et al. , 2000	51789
et al.	51789
2000	51797
NF-positive fibers	51810
small dorsal hemisection lesion gaps , which were infiltrated by numerous host cells expressing the p75-NGF receptor	51869
small dorsal hemisection lesion gaps	51869
numerous host cells	51933
the p75-NGF receptor	51964
the present study	51989
such a spontaneous response of endogenous tissue repair	52008
such a spontaneous response	52008
endogenous tissue repair	52039
the extent of the injury	52084
the extent	52084
the injury	52098
the dorsal half of the spinal cord over a distance of 2 mm	52139
the dorsal half	52139
the spinal cord over a distance of 2 mm	52158
the spinal cord	52158
a distance of 2 mm	52179
a distance	52179
2 mm	52193
Control animals , which did not receive a transplant ,	52199
Control animals	52199
a transplant	52238
only a minor penetration of NF-positive axons	52266
only a minor penetration	52266
NF-positive axons	52294
the lesion site	52317
This	52334
the lack of host cell infiltration	52359
the lack	52359
host cell infiltration	52371
the lesion site	52399
the contrary	52419
numerous NFpositive axons	52433
the graft/lesion site of OEC/ONFtransplanted animals	52470
the graft/lesion site	52470
OEC/ONFtransplanted animals	52495
OEC/ONF	52545
the surface area of the OEC/ONF -- biomatrix complexes upon transplantation	52574
the surface area of the OEC/ONF	52574
the surface area	52574
the OEC/ONF	52594
biomatrix complexes upon transplantation	52606
biomatrix complexes	52606
transplantation	52631
NF-positive axons	52648
the complex	52691
Many host cells , presumably Schwann cells -LRB- as we observed immunoreactivity for the p75 - NGF receptor -RRB- and fibroblasts -LRB- Bunge et al. , 1997 ; Pasterkamp et al. , 1999 -RRB- ,	52704
Many host cells	52704
Many host	52704
cells	52714
Schwann cells -LRB- as we observed immunoreactivity for the p75 - NGF receptor -RRB- and fibroblasts -LRB- Bunge et al. , 1997 ; Pasterkamp et al. , 1999 -RRB-	52732
Schwann cells -LRB- as we observed immunoreactivity for the p75 - NGF receptor -RRB- and fibroblasts	52732
Schwann cells -LRB- as we observed immunoreactivity for the p75 - NGF receptor -RRB-	52732
Schwann cells	52732
we	52750
immunoreactivity	52762
the p75 - NGF receptor	52783
the p75	52783
NGF receptor	52792
fibroblasts	52810
Bunge	52823
et al. , 1997 ; Pasterkamp et al. , 1999	52829
et al.	52829
1997 ; Pasterkamp et al.	52837
1997	52837
Pasterkamp et al.	52843
Pasterkamp	52843
et al.	52854
1999	52862
the biomatrix complexes -LRB- possibly by growing within the pores of the biomatrix -RRB-	52890
the biomatrix complexes	52890
growing within the pores of the biomatrix	52927
growing	52927
within the	52935
the biomatrix	52955
These invading host cells	52971
These	52971
host cells	52986
the stimulation of NF ingrowth	53013
the stimulation	53013
NF ingrowth	53032
the graft	53049
All the NF-positive axons in the graft / lesion site were GAP43/B50-positive , confirming their regrowing / sprouting nature .	53060
All the NF-positive axons	53060
the graft / lesion site were GAP43/B50-positive , confirming their regrowing / sprouting nature	53089
the graft	53089
lesion site	53100
their	53148
nature	53175
the origin of these ingrowing axons	53192
the origin	53192
these ingrowing axons	53206
a CS and raphespinal origin	53244
these ingrowing axons	53302
a peripheral origin -LRB- e.g. CGRP immunoreactive axons -RRB- , as has been described previously in a less severe injury model -LRB- Brook et al. , 2000 -RRB-	53333
a peripheral origin	53333
immunoreactive axons	53364
a less severe injury model -LRB- Brook et al. , 2000 -RRB-	53423
a less severe injury model	53423
Brook	53451
et al. , 2000	53457
et al.	53457
2000	53465
OEC/ONF-transplanted animals	53488
a 10-fold increase	53524
NF-positive axon growth	53546
the graft/lesion site	53575
animals	53620
our transplantation strategy	53635
an argument	53683
the exact mechanisms stimulating neurofilamentpositive axon growth into the transplanted OEC/ONF	53712
the exact mechanisms	53712
neurofilamentpositive axon growth	53745
the transplanted OEC/ONF	53784
biomatrix complexes	53809
it	53833
the transplanted OEC/ONF or the biomatrix	53836
the transplanted OEC/ONF	53836
the biomatrix	53864
Pilot experiments by our group	53879
Pilot experiments	53879
our group	53900
a similar quantification procedure	53917
there	53965
no difference between the ingrowth of NF axons	53975
no difference	53975
the ingrowth of NF axons	53997
the ingrowth	53997
NF axons	54013
OEC/ONF -- biomatrix grafts or biomatrix grafts without OEC/ONF	54027
OEC/ONF	54027
biomatrix grafts or biomatrix grafts without OEC/ONF	54035
biomatrix grafts or biomatrix grafts	54035
OEC/ONF	54080
the biomatrix itself	54096
the biomatrix	54096
NF axon ingrowth	54156
the graft/lesion site	54178
This effect	54201
the host cells	54239
the biomatrix	54263
transplantation	54283
Survival and migration of transplanted OEC/ONF	54300
Survival and migration	54300
transplanted OEC/ONF	54326
no Hoechst-prelabeled-positive cells	54356
the spinal lesion gap , many prelabeled cells	54418
the spinal lesion gap	54418
many prelabeled cells	54441
the injection areas -LRB- Fig. 1 -RRB-	54484
the injection areas	54484
Fig. 1	54505
A minority of these cells	54514
A minority	54514
these cells	54528
the p75-NGF receptor , which was expected because of the presence of this receptor on the OEC in mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54550
the p75-NGF receptor	54550
the presence of this receptor on the OEC in mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54602
the presence	54602
this receptor on the OEC in mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54618
this receptor	54618
the OEC in mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54635
the OEC	54635
mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54646
mixed OEC/ONF cultures	54646
Li	54670
et al. , 1998 ; Deumens et al. , 2004	54673
et al.	54673
1998 ; Deumens et al.	54681
1998	54681
Deumens et al.	54687
Deumens	54687
et al.	54695
2004	54703
Hoechst	54719
leak	54731
transplanted cells	54743
host cells -LRB- Iwashita et al. , 2000 -RRB-	54772
host cells	54772
Iwashita	54784
et al. , 2000	54793
et al.	54793
2000	54801
the condensed presence of Hoechst-positive cells and the p75-NGF receptor immunoreactivity in a subpopulation of Hoechst cells	54808
the condensed presence of Hoechst-positive cells	54808
the condensed presence	54808
Hoechst-positive cells	54834
the p75-NGF receptor immunoreactivity in a subpopulation of Hoechst cells	54861
the p75-NGF receptor immunoreactivity	54861
a subpopulation of Hoechst cells	54902
a subpopulation	54902
Hoechst cells	54921
the Hoechst-positive cells within the injection areas	54949
the Hoechst-positive cells	54949
the injection areas	54983
transplanted OEC/ONF that survived	55007
transplanted OEC/ONF	55007
the injected OEC/ONF	55051
transplantation	55081
the injection areas	55102
they	55123
the injured spinal cord	55151
There	55176
some essential differences between our study lacking OEC / ONF migration and other studies showing migration of olfactory glia after injection into the injured spinal cord -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB- , including the specific olfactory glia culture and the injection procedures	55186
some essential differences	55186
our study lacking OEC / ONF migration and other studies showing migration of olfactory glia after injection into the injured spinal cord -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB- , including the specific olfactory glia culture and the injection procedures	55221
our study	55221
OEC / ONF migration and other studies showing migration of olfactory glia after injection into the injured spinal cord -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	55239
OEC / ONF migration and other studies	55239
OEC	55239
ONF migration and other studies	55244
ONF migration	55244
other studies	55262
migration of olfactory glia	55284
migration	55284
olfactory glia	55297
injection	55318
the injured spinal cord	55333
Li	55358
et al. , 1998 ; Ramon-Cueto et al. , 2000	55361
et al.	55361
1998 ; Ramon-Cueto et al.	55369
1998	55369
Ramon-Cueto et al.	55375
Ramon-Cueto	55375
et al.	55387
2000	55395
the specific olfactory glia culture and the injection procedures	55412
the specific olfactory glia culture	55412
the injection procedures	55452
the influence of any of those factors on migration of the transplanted olfactory glia	55487
the influence	55487
any of those factors on migration of the transplanted olfactory glia	55504
any	55504
those factors on migration of the transplanted olfactory glia	55511
those factors	55511
migration of the transplanted olfactory glia	55528
migration	55528
the transplanted olfactory glia	55541
The lack of survival of transplanted OEC/ONF on the biomatrices and the lack of migration of injected OEC/ONF	55599
The lack	55599
survival of transplanted OEC/ONF on the biomatrices and the lack of migration of injected OEC/ONF	55611
survival	55611
transplanted OEC/ONF on the biomatrices and the lack of migration of injected OEC/ONF	55623
transplanted OEC/ONF on the biomatrices	55623
transplanted OEC/ONF	55623
the biomatrices	55647
the lack of migration of injected OEC/ONF	55667
the lack	55667
migration of injected OEC/ONF	55679
migration	55679
injected OEC/ONF	55692
CS axon regrowth	55726
no OEC/ONF continuum	55751
Pathological processes , like hemorrhage and inflammation ,	55785
Pathological processes	55785
hemorrhage and inflammation	55814
the injured spinal cord environment -LRB- Dusart and Schwab , 1994 -RRB-	55859
spinal cord environment -LRB- Dusart and Schwab , 1994 -RRB-	55871
spinal cord environment	55871
Dusart and Schwab , 1994	55896
Dusart	55896
Schwab , 1994	55907
Schwab	55907
1994	55915
The concentration of toxic substances released from such processes	55922
The concentration	55922
toxic substances released from such processes	55943
toxic substances	55943
such processes	55974
spinal lesions which are larger -LRB- Wagner et al. , 1978 -RRB-	56006
spinal lesions	56006
Wagner	56039
et al. , 1978	56046
et al.	56046
1978	56054
this	56072
the migration of the transplanted OEC/ONF within the host spinal tissue	56097
the migration	56097
the transplanted OEC/ONF within the host spinal tissue	56114
the transplanted OEC/ONF	56114
the host spinal tissue	56146
The lack of OEC/ONF migration within the host spinal tissue	56170
The lack	56170
OEC/ONF migration within the host spinal tissue	56182
OEC/ONF migration	56182
the host spinal tissue	56207
others who transplanted purified OEC cultures into the host spinal tissue close to large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	56251
others	56251
OEC cultures	56284
the host spinal tissue close	56302
large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	56334
large spinal lesion gaps	56334
Chuah	56360
et al. , 2004	56366
et al.	56366
2004	56374
it	56388
multiple cell injections	56411
a continuum of these cells	56446
a continuum	56446
these cells	56461
spinal cords	56478
large lesion gaps	56496
this	56523
the lack of OEC/ONF survival within the large spinal lesion gap	56529
the lack	56529
OEC/ONF survival within the large spinal lesion gap	56541
OEC/ONF survival	56541
the large spinal lesion gap	56565
contrast with previous findings -LRB- Sasaki et al. , 2004 -RRB-	56599
contrast	56599
previous findings -LRB- Sasaki et al. , 2004 -RRB-	56613
previous findings	56613
Sasaki	56632
et al. , 2004	56639
et al.	56639
2004	56647
a combination of several causes	56658
a combination	56658
several causes	56675
the putative high concentration of toxic substances released by pathological processes	56714
the putative high concentration	56714
toxic substances released by pathological processes	56749
toxic substances	56749
pathological processes	56778
the survival of OEC/ONF-transplanted into these large lesion gaps	56819
the survival	56819
OEC/ONF-transplanted into these large lesion gaps	56835
these large lesion	56861
the OEC/ONF	56892
the biomatrix surface	56921
the injured spinal tissue	56950
the toxic substances	56977
these transplanted OEC / ONF	57024
these transplanted OEC	57024
ONF	57048
previous studies	57061
the survival of transplanted cells in identical large lesion gaps when the cells were embedded in collagen type I matrices and were thereby	57096
the survival	57096
transplanted cells in identical large lesion gaps when the cells were embedded in collagen type I matrices and were thereby	57112
transplanted cells	57112
identical large lesion gaps when the cells were embedded in collagen type I matrices and were thereby	57134
identical large lesion gaps	57134
the cells	57167
collagen type I matrices	57194
collagen type	57194
I matrices	57208
the injured spinal cord environment -LRB- Joosten et al. , 2004 -RRB-	57262
the injured spinal cord environment	57262
Joosten	57299
et al. , 2004	57307
et al.	57307
2004	57315
the acutely injured spinal cord	57330
acutely injured spinal cord	57334
a negative effect	57385
OEC proliferation and increase OEC apoptosis	57406
OEC proliferation	57406
increase OEC apoptosis	57428
either uninjured or chronically injured spinal cord	57466
uninjured	57473
chronically injured spinal cord	57486
tissue -LRB- Woodhouse et al. , 2005 -RRB-	57518
tissue	57518
Woodhouse	57526
et al. , 2005	57536
et al.	57536
2005	57544
Third , optimal numbers of OEC/ONF	57551
Third	57551
optimal numbers of OEC/ONF	57558
optimal numbers	57558
OEC/ONF	57577
OEC/ONF	57618
biomatrix complexes during 4 days in vitro -LRB- Deumens et al. , 2004 -RRB-	57626
biomatrix complexes during 4 days in vitro	57626
biomatrix complexes	57626
4 days	57653
Deumens	57670
et al. , 2004	57678
et al.	57678
2004	57686
These numbers	57693
the survival of the transplanted OEC/ONF within the spinal lesion sites upon transplantation of these complexes	57759
the survival	57759
the transplanted OEC/ONF within the spinal lesion sites upon transplantation of these complexes	57775
the transplanted OEC/ONF	57775
the spinal lesion sites upon transplantation of these complexes	57807
the spinal lesion sites	57807
transplantation of these complexes	57836
transplantation	57836
these complexes	57855
there	57880
some differences between our study set-up and that of Sasaki and colleagues which could affect OEC survival , including a difference in lesion type , studied time points after injury , and cell preparation protocols	57895
some differences between our study set-up	57895
some differences	57895
our study set-up	57920
Sasaki	57949
colleagues which could affect OEC survival , including a difference in lesion type , studied time points after injury , and cell preparation protocols	57960
colleagues	57960
OEC survival , including a difference in lesion type , studied time points after injury , and cell preparation protocols	57990
OEC survival , including a difference in lesion type , studied time points after injury	57990
OEC survival , including a difference in lesion type ,	57990
OEC survival	57990
a difference in lesion type	58014
a difference	58014
lesion type	58030
time points	58051
injury	58069
cell preparation protocols	58081
the specific use of poly -LRB- D , L -RRB- - lactide matrices to transplant OEC/ONF into the large spinal lesion gaps	58118
the specific use	58118
poly -LRB- D , L -RRB- - lactide matrices to transplant OEC/ONF into the large spinal lesion gaps	58138
poly	58138
lactide matrices to transplant OEC/ONF into the large spinal lesion gaps	58148
OEC/ONF	58179
the large spinal lesion gaps	58192
OEC/ONF survival	58250
Degradation of poly -LRB- D , L -RRB- - lactides	58268
Degradation	58268
poly -LRB- D , L -RRB- - lactides	58283
poly	58283
lactides	58293
example associated with a lowering of the pH -LRB- Mainil-Varlet et al. , 1997 -RRB- , which may impair OEC / ONF survival	58309
example	58309
a lowering of the pH -LRB- Mainil-Varlet et al. , 1997 -RRB- , which may impair OEC / ONF survival	58333
a lowering	58333
the pH -LRB- Mainil-Varlet et al. , 1997 -RRB- , which may impair OEC / ONF survival	58347
the pH -LRB- Mainil-Varlet et al. , 1997 -RRB-	58347
the pH	58347
Mainil-Varlet	58355
et al. , 1997	58369
et al.	58369
1997	58377
OEC / ONF survival	58401
OEC	58401
ONF survival	58406
biomaterials other than poly -LRB- D , L -RRB- - lactides	58427
biomaterials	58427
poly -LRB- D , L -RRB- - lactides	58451
poly -LRB- D , L -RRB-	58451
poly	58451
lactides	58461
combination	58487
OEC/ONF for their effects	58504
OEC/ONF	58504
their effects	58516
long-distance CS axon regrowth across large spinal lesion gaps	58533
long-distance CS axon regrowth	58533
large spinal lesion gaps	58571
Functional recovery The multifactorial transplantation strategy	58597
Functional recovery	58597
The multifactorial transplantation strategy	58617
modest recovery of fine locomotor parameters -LRB- Fig. 5 -RRB-	58672
modest recovery	58672
fine locomotor parameters -LRB- Fig. 5 -RRB-	58691
fine locomotor parameters	58691
Fig. 5	58718
The -LRB- incomplete -RRB- recovery	58727
locomotor functions -LRB- swing speed and stride length of the hind limb -RRB-	58756
locomotor functions	58756
swing speed and stride length of the hind limb	58777
swing speed and stride length	58777
the hind limb	58810
9 weeks	58841
injury , which may reflect an involvement of axonal regrowth	58855
injury	58855
an involvement of axonal regrowth	58881
an involvement	58881
axonal regrowth	58899
the current knowledge	58921
regrowth of individual axon tracts and functional recovery	58961
regrowth	58961
individual axon tracts and functional recovery	58973
individual axon tracts	58973
functional recovery	59000
Deumens et al. , 2005	59035
Deumens	59035
et al.	59043
2005	59051
an improvement in stride length as demonstrated in this study	59072
an improvement	59072
stride length as demonstrated in this study	59090
stride length	59090
this study	59123
enhanced regrowth of injured CS axons across a thoracic dorsal hemisection lesion site and back into the caudal host tissue -LRB- Bregman et al. , 1995 -RRB-	59177
enhanced regrowth	59177
injured CS axons across a thoracic dorsal hemisection lesion site and back into the caudal host tissue -LRB- Bregman et al. , 1995 -RRB-	59198
injured CS axons	59198
a thoracic dorsal hemisection lesion site	59222
the caudal host tissue -LRB- Bregman et al. , 1995 -RRB-	59278
the caudal host tissue	59278
Bregman	59302
et al. , 1995	59310
et al.	59310
1995	59318
others	59338
a relation between the CS tract and stride length of the hind limbs -LRB- Starkey et al. , 2004 -RRB-	59359
a relation	59359
the CS tract and stride length of the hind limbs -LRB- Starkey et al. , 2004 -RRB-	59378
the CS tract and stride length	59378
the hind limbs -LRB- Starkey et al. , 2004 -RRB-	59412
the hind limbs	59412
Starkey	59428
et al. , 2004	59436
et al.	59436
2004	59444
our study	59454
no relation between regrowth of the injured CS tract axons and recovery of stride length	59465
no relation	59465
regrowth of the injured CS tract axons and recovery of stride length	59485
regrowth of the injured CS tract axons	59485
regrowth	59485
the injured CS tract axons	59497
recovery of stride length	59528
recovery	59528
stride length	59540
the effects on injured CS axons	59587
the effects	59587
injured CS axons	59602
responses of other axon tracts descending from the brain that are more likely to be linked with stride length	59637
responses	59637
other axon tracts descending from the brain that are more likely to be linked with stride length	59650
other axon tracts	59650
the brain that are more likely to be linked with stride length	59684
the brain	59684
stride length	59733
this	59756
formation of new intraspinal relay circuits as described by others -LRB- Bareyre et al. , 2004 -RRB-	59762
formation	59762
new intraspinal relay circuits as described by others -LRB- Bareyre et al. , 2004 -RRB-	59775
new intraspinal relay circuits	59775
others -LRB- Bareyre et al. , 2004 -RRB-	59822
others	59822
Bareyre	59830
et al. , 2004	59838
et al.	59838
2004	59846
The effect of our intervention on locomotion	59872
The effect	59872
our intervention on locomotion	59886
our intervention	59886
locomotion	59906
only a small subset of locomotor parameters	59934
only a small subset	59934
locomotor parameters	59957
This	59979
the spinal cord injury model	60019
we	60053
the first to evaluate behavioral impairments after dorsal hemisection injury quantitatively in such a highly detailed , objective , and sensitive manner using the CatWalk gait analysis	60068
behavioral impairments	60090
dorsal hemisection injury	60119
such a highly detailed , objective , and sensitive manner using the CatWalk gait analysis	60163
a highly detailed , objective ,	60168
a highly detailed	60168
objective	60187
sensitive manner using the CatWalk gait analysis	60202
sensitive manner	60202
the CatWalk gait analysis	60225
a behavioral level	60255
the CatWalk	60275
the control animals in our study	60299
the control animals	60299
our study	60322
The majority of locomotor parameters assessed in the CatWalk	60375
The majority	60375
locomotor parameters assessed in the CatWalk	60391
locomotor parameters	60391
the CatWalk	60424
these unaffected parameters	60463
the regularity index -LRB- RI -RRB- , which is strongly involved in coordination	60494
the regularity index	60494
RI	60516
coordination	60551
Implementation of RI as an objective parameter for coordination into the BBB test	60565
Implementation	60565
RI as an objective parameter for coordination into the BBB test	60583
RI	60583
an objective parameter for coordination into the BBB test	60589
an objective parameter	60589
coordination into the BBB test	60616
coordination	60616
the BBB test	60634
a significant increase of the BBB score of both transplanted and control animals	60659
a significant increase	60659
the BBB score of both transplanted and control animals	60685
the BBB score of both transplanted	60685
the BBB score	60685
both transplanted	60702
control animals	60724
a previous study of our group	60744
a previous study	60744
our group	60764
a spinal cord contusion injury	60780
RI implementation into the BBB	60812
RI implementation	60812
the BBB	60835
a strong enhancement	60850
the sensitivity of the BBB -LRB- Koopmans et al. , 2005 -RRB-	60874
the sensitivity	60874
the BBB -LRB- Koopmans et al. , 2005 -RRB-	60893
the BBB	60893
Koopmans	60902
et al. , 2005	60911
et al.	60911
2005	60919
a significant difference in BBB scores	60932
a significant difference	60932
BBB scores	60960
enriched housed animals as compared to normally housed animals	60991
enriched	60991
animals	61007
normally housed animals	61030
implementation of the RI	61065
implementation	61065
the RI	61083
the BBB -LRB- Koopmans et al. , 2005 -RRB-	61093
the BBB	61093
Koopmans	61102
et al. , 2005	61111
et al.	61111
2005	61119
the RI	61131
the BBB	61159
the present study	61170
the BBB scores of transplanted and control animals	61189
the BBB scores	61189
transplanted and control animals	61207
transplanted	61207
control animals	61224
a similar extent	61253
no inter-group difference	61282
This more sensitive and objective behavioral analysis	61327
the rather limited behavioral impairment	61398
dorsal hemisection injury	61445
an only very small window for functional recovery	61485
an only very small window	61485
functional recovery	61515
Conclusions Our multifactorial transplantation strategy	61536
Conclusions	61536
Our multifactorial transplantation strategy	61548
regrowth of injured CS axons	61623
regrowth	61623
injured CS axons	61635
large spinal lesion gaps	61659
an enhanced presence of injured CS axons	61694
an enhanced presence	61694
injured CS axons	61718
rostral	61757
the lesion gap , which was paralleled by the penetration of many axons into the graft and by modest locomotor recovery	61768
the lesion gap	61768
the penetration of many axons	61808
the penetration	61808
many axons	61827
the graft	61843
modest locomotor recovery	61860
Future studies	61887
optimalization of the transplantation strategy	61915
optimalization	61915
the transplantation strategy	61933
issues , such as -LRB- 1 -RRB- the limited migration of transplanted OEC/ONF within the host tissue of spinal cords with large lesion gaps and -LRB- 2 -RRB- the problems with OEC / ONF survival on poly -LRB- D , L -RRB- - lactide matrices within large lesion gaps	61982
issues	61982
-LRB- 1 -RRB- the limited migration of transplanted OEC/ONF within the host tissue of spinal cords with large lesion gaps and -LRB- 2 -RRB- the problems with OEC / ONF survival on poly -LRB- D , L -RRB- - lactide matrices within large lesion gaps	61998
-LRB- 1 -RRB- the limited migration of transplanted OEC/ONF within the host tissue of spinal cords with large lesion gaps	61998
the limited migration	62002
transplanted OEC/ONF within the host tissue of spinal cords with large lesion gaps	62027
transplanted OEC/ONF	62027
the host tissue of spinal cords with large lesion gaps	62055
the host tissue	62055
spinal cords with large lesion gaps	62074
spinal cords	62074
large lesion gaps	62092
-LRB- 2 -RRB- the problems with OEC / ONF survival on poly -LRB- D , L -RRB- - lactide matrices within large lesion gaps	62114
-LRB- 2 -RRB- the problems with OEC / ONF survival on poly -LRB- D , L -RRB-	62114
the problems	62118
OEC / ONF survival on poly -LRB- D , L -RRB-	62136
OEC / ONF survival on poly	62136
OEC	62136
ONF survival on poly	62141
ONF survival	62141
poly	62157
lactide matrices within large lesion gaps	62167
lactide matrices	62167
large lesion gaps	62191
we	62223
the combined use of detailed and sensitive behavioral tests such as the CatWalk gait analysis and a spinal injury model with a higher degree of behavioral impairment	62236
the combined use	62236
detailed and sensitive behavioral tests such as the CatWalk gait analysis and a spinal injury model	62256
detailed and sensitive behavioral tests	62256
the CatWalk gait analysis and a spinal injury model	62304
the CatWalk gait analysis	62304
a spinal injury model	62334
a higher degree of behavioral impairment	62361
a higher degree	62361
behavioral impairment	62380
a much wider behavioral window for the determination of therapeutic effects	62419
a much wider behavioral window	62419
the determination of therapeutic effects	62454
the determination	62454
therapeutic effects	62475
Acknowledgments The authors thank Dr. Y. Li and Prof. Dr. G. Raisman for extending their knowledge on OEC/ONF culturing to our laboratory and Marijke Lemmens and Dr. Jos Prickaerts for their assistance with the immunohistochemical stainings and expertise regarding picture processing , respectively .	62496
Acknowledgments The authors thank Dr. Y. Li and Prof. Dr. G. Raisman for extending their knowledge on OEC/ONF culturing to our laboratory and Marijke Lemmens and Dr. Jos Prickaerts for their assistance	62496
Acknowledgments	62496
The authors	62512
Dr. Y. Li and Prof. Dr. G. Raisman for extending their knowledge on OEC/ONF culturing to our laboratory and Marijke Lemmens and Dr. Jos Prickaerts for their assistance	62530
Dr. Y. Li and Prof. Dr. G. Raisman	62530
their knowledge	62579
OEC/ONF culturing	62598
our laboratory and Marijke Lemmens and Dr. Jos Prickaerts for their assistance	62619
our laboratory and Marijke Lemmens	62619
our laboratory	62619
Marijke Lemmens	62638
Dr. Jos Prickaerts for their assistance	62658
Dr. Jos Prickaerts	62658
their assistance	62681
the immunohistochemical stainings and expertise	62703
picture processing , respectively	62761
picture processing	62761
The authors	62795
Lou Kirkels -LRB- IDEE , Maastricht -RRB- for his expertise with respect	62828
Lou Kirkels -LRB- IDEE , Maastricht -RRB-	62828
Lou Kirkels	62828
IDEE	62841
Maastricht	62847
his expertise with respect	62863
his expertise	62863
respect	62882
the injection procedures	62893
The RT97 monoclonal antibody , developed by Dr. J. Wood ,	62919
The RT97 monoclonal antibody	62919
Dr. J. Wood	62962
the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD	62993
the Developmental Studies	62993
Hybridoma Bank	63019
the auspices of the NICHD	63050
the auspices	63050
the NICHD	63066
The University of Iowa , Department of Biological Sciences , Iowa City , IA 52242 , USA	63094
The University	63094
Iowa , Department of Biological Sciences , Iowa City , IA 52242 , USA	63112
Iowa , Department	63112
Biological Sciences , Iowa City , IA 52242 , USA	63132
Biological Sciences	63132
Iowa City	63153
IA 52242	63164
USA	63174
This work	63179
the International Spinal Research Trust -LRB- ISRT ; STR057 to E.A.J.J. -RRB-	63203
the International Spinal Research Trust	63203
ISRT ; STR057 to E.A.J.J.	63244
ISRT	63244
STR057 to E.A.J.J.	63250
STR057	63250
E.A.J.J.	63260
References Bareyre , F.M. , Kerschensteiner , M. , Raineteau , O. , Mettenleiter , T.C. , Weinmann , O. , Schwab , M.E. , 2004 .	63271
References	63271
Bareyre , F.M. , Kerschensteiner , M. , Raineteau , O. , Mettenleiter , T.C. , Weinmann , O. , Schwab , M.E. , 2004	63282
Bareyre , F.M. , Kerschensteiner , M. , Raineteau , O. , Mettenleiter , T.C. , Weinmann , O. , Schwab , M.E. ,	63282
2004	63381
The injured spinal cord	63387
a new intraspinal circuit in adult rats	63431
a new intraspinal circuit	63431
adult rats	63460
Nat .	63472
Neurosci	63477
7 , 269 -- 277 .	63487
7	63487
269 -- 277	63490
Barnett , S.C. , Chang , L. , 2004 .	63499
Barnett , S.C. , Chang , L.	63499
2004	63525
Olfactory ensheathing cells and CNS repair : going solo or in need of a friend ?	63531
Olfactory ensheathing cells and CNS repair	63531
going solo or in need of a friend	63575
going solo	63575
in need of a friend	63589
need	63592
a friend	63600
Trends Neurosci .	63610
Trends	63610
Neurosci	63617
27 , 54 -- 60 .	63627
27	63627
54 -- 60	63631
Basso , D.M. , Beattie , M.S. , Bresnahan , J.C. , 1995 .	63638
Basso , D.M. , Beattie , M.S. , Bresnahan , J.C.	63638
1995	63683
A sensitive and reliable locomotor rating scale for open field testing in rats .	63689
A sensitive and reliable locomotor	63689
rating scale for open field testing in rats	63724
rating scale	63724
open field testing in rats	63741
open field testing	63741
rats	63763
J. Neurotrauma 12 , 1 -- 21 .	63769
J. Neurotrauma 12 , 1	63769
21	63790
Bregman , B.S. , Kunkel-Bagden , E. , Schnell , L. , Dai , H.N. , Gao , D. , Schwab , M.E. , 1995 .	63794
Bregman , B.S. , Kunkel-Bagden , E. , Schnell , L. , Dai , H.N. , Gao , D. , Schwab , M.E.	63794
1995	63875
Recovery from spinal cord injury	63881
Recovery	63881
spinal cord injury	63895
antibodies to neurite growth inhibitors	63926
antibodies	63926
neurite growth inhibitors	63940
Nature 378 , 498 -- 501 .	63967
Nature 378 , 498	63967
501	63983
Brook , G.A. , Houweling , D.A. , Gieling , R.G. , Hermanns , T. , Joosten , E.A. , Bar , D.P. , Gispen , W.H. , Schmitt , A.B. , Leprince , P. , Noth , J. , Nacimiento , W. , 2000 .	63988
Brook , G.A. , Houweling , D.A. , Gieling , R.G. , Hermanns , T. , Joosten , E.A. , Bar , D.P. , Gispen , W.H. , Schmitt , A.B. , Leprince , P. , Noth , J. , Nacimiento , W.	63988
2000	64142
endogenous tissue repair following experimental spinal cord injury in the rat : involvement of cell adhesion molecules L1 and NCAM	64158
endogenous tissue repair	64158
experimental spinal cord injury in the rat : involvement of cell adhesion molecules L1 and NCAM	64193
experimental spinal cord injury in the rat	64193
experimental spinal cord injury	64193
the rat	64228
involvement of cell adhesion molecules L1 and NCAM	64237
involvement	64237
cell adhesion molecules L1 and NCAM	64252
cell adhesion molecules L1	64252
NCAM	64283
Eur	64289
J. Neurosci .	64294
12 , 3224 -- 3238 .	64307
12	64307
3224 -- 3238	64311
Bunge , R.P. , Puckett , W.R. , Hiester , E.D. , 1997 .	64322
Bunge , R.P. , Puckett , W.R. , Hiester , E.D.	64322
1997	64365
Observations on the pathology of several types of human spinal cord injury , with emphasis on the astrocyte response to penetrating injuries .	64371
Observations	64371
the pathology	64387
several types	64404
human spinal cord injury , with emphasis	64421
human spinal cord injury	64421
emphasis	64452
the astrocyte response	64464
injuries	64502
Adv. Neurol .	64512
72 , 305 -- 315 .	64525
72	64525
305 -- 315	64529
Bunn , H.J. , Woltmann , G. , Grigg , J. , 2002 .	64538
Bunn , H.J. , Woltmann , G. , Grigg , J.	64538
2002	64575
Applicability of laser scanning cytometry to study paediatric alveolar macrophages .	64581
Applicability	64581
laser scanning cytometry	64598
paediatric alveolar macrophages	64632
Eur	64665
Respir	64670
J. 20 , 1437 -- 1443 .	64678
J. 20 , 1437	64678
1443	64690
Chuah , M.I. , Choi-Lundberg , D. , Weston , S. , Vincent , A.J. , Chung , R.S. , Vickers , J.C. , West , A.K. , 2004 .	64696
Chuah , M.I. , Choi-Lundberg , D. , Weston , S. , Vincent , A.J. , Chung , R.S. , Vickers , J.C. , West , A.K.	64696
2004	64795
Olfactory ensheathing cells	64801
collateral	64837
the injured adult rat spinal cord	64868
Exp .	64903
Neurol	64908
185 , 15 -- 25 .	64916
185	64916
15 -- 25	64921
Coumans , J.V. , Lin , T.T. , Dai , H.N. , MacArthur , L. , McAtee , M. , Nash , C. , Bregman , B.S. , 2001 .	64928
Coumans , J.V. , Lin , T.T. , Dai , H.N. , MacArthur , L. , McAtee , M. , Nash , C. , Bregman , B.S.	64928
2001	65017
Axonal regeneration and functional recovery after complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins .	65023
Axonal regeneration and functional recovery	65023
complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins	65073
complete spinal cord transection	65073
rats by delayed treatment with transplants and neurotrophins	65109
rats	65109
delayed treatment with transplants and neurotrophins	65117
delayed treatment	65117
transplants and neurotrophins	65140
J. Neurosci .	65171
21 , 9334 -- 9344 .	65184
21	65184
9334 -- 9344	65188
Deumens , R. , Koopmans , G.C. , Den Bakker , C.G. , Maquet , V. , Blacher , S. , Honig , W.M. , Jerome , R. , Pirard , J.P. , Steinbusch , H.W. , Joosten , E.A. , 2004 .	65199
Deumens , R. , Koopmans , G.C. , Den Bakker , C.G. , Maquet , V. , Blacher , S. , Honig , W.M. , Jerome , R. , Pirard , J.P. , Steinbusch , H.W. , Joosten , E.A.	65199
2004	65343
Alignment of glial cells	65349
Alignment	65349
glial cells	65362
directional neurite growth of CNS neurons	65385
directional neurite growth	65385
CNS neurons	65415
Neuroscience 125 , 591 -- 604 .	65437
Neuroscience 125	65437
591 -- 604	65455
Deumens , R. , Koopmans , G.C. , Joosten , E.A. , 2005 .	65464
Deumens , R. , Koopmans , G.C. , Joosten , E.A.	65464
2005	65508
Regeneration of descending axon tracts after spinal cord injury .	65514
Regeneration	65514
axon tracts	65541
spinal cord injury	65559
Prog .	65579
Neurobiol	65585
77 , 57 -- 89 .	65596
77	65596
57 -- 89	65600
Dusart , I. , Schwab , M.E. , 1994 .	65607
Dusart , I. , Schwab , M.E.	65607
1994	65633
Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord .	65639
Secondary cell	65639
death and the inflammatory reaction	65654
death	65654
the inflammatory reaction	65664
dorsal hemisection of the rat spinal cord	65696
dorsal hemisection	65696
the rat spinal cord	65718
Eur	65739
J. Neurosci .	65744
6 , 712 -- 724 .	65757
6	65757
712 -- 724	65760
Fawcett , J.W. , 1997 .	65769
Fawcett , J.W.	65769
1997	65784
Astrocytic and neuronal factors affecting axon regeneration in the damaged central nervous system .	65790
Astrocytic and neuronal factors	65790
axon regeneration in the damaged central nervous system	65832
axon regeneration	65832
the damaged central nervous system	65853
Cell Tissue Res .	65889
Cell Tissue	65889
Res	65901
290 , 371 -- 377 .	65906
290	65906
371 -- 377	65911
Franceschini , I.A. , Barnett , S.C. , 1996 .	65920
Franceschini , I.A. , Barnett , S.C.	65920
1996	65955
Low-affinity NGF-receptor and E-NCAM expression	65961
Low-affinity NGF-receptor	65961
E-NCAM expression	65991
two types of olfactory nerve ensheathing cells that share a common lineage	66016
two types	66016
olfactory nerve ensheathing cells	66029
a common lineage	66074
Dev .	66092
Biol	66097
173 , 327 -- 343 .	66103
173	66103
327 -- 343	66108
Goldshmit , Y. , Galea , M.P. , Wise , G. , Bartlett , P.F. , Turnley , A.M. , 2004 .	66117
Goldshmit , Y. , Galea , M.P. , Wise , G. , Bartlett , P.F. , Turnley , A.M.	66117
2004	66186
Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice .	66192
Axonal regeneration and lack	66192
astrocytic gliosis	66224
EphA4-deficient mice	66246
J. Neurosci .	66268
24 , 10064 -- 10073 .	66281
24	66281
10064 -- 10073	66285
GrandPre , T. , Li , S. , Strittmatter , S.M. , 2002 .	66298
GrandPre , T. , Li , S. , Strittmatter , S.M.	66298
2002	66340
Nogo-66 receptor antagonist peptide	66346
Nogo-66 receptor	66346
antagonist peptide	66363
axonal regeneration	66391
Nature 417 , 547 -- 551 .	66412
Nature 417 , 547	66412
551	66428
Grill , R. , Blesch , A. , Gage , F.H. , Tuszynski , M.H. , 1997 .	66433
Grill	66433
R. , Blesch , A. , Gage , F.H. , Tuszynski , M.H. , 1997	66440
R.	66440
Blesch	66444
A.	66452
Gage	66456
F.H.	66462
Tuszynski	66468
M.H.	66479
1997	66485
Cellular delivery of neurotrophin-3	66491
Cellular delivery	66491
neurotrophin-3	66512
corticospinal axonal growth and partial functional recovery	66536
axonal growth	66550
spinal cord injury	66602
J. Neurosci .	66622
17 , 5560 -- 5572 .	66635
17	66635
5560 -- 5572	66639
Hamers , F.P. , Lankhorst , A.J. , van Laar , T.J. , Veldhuis , W.B. , Gispen , W.H. , 2001 .	66650
Hamers , F.P. , Lankhorst , A.J. , van Laar , T.J. , Veldhuis , W.B. , Gispen , W.H.	66650
2001	66727
Automated quantitative gait analysis during overground locomotion in the rat : its application to spinal cord contusion and transection injuries .	66733
Automated quantitative gait analysis during overground locomotion in the rat	66733
Automated quantitative gait analysis	66733
overground locomotion	66777
the rat	66802
its application to spinal cord contusion and transection injuries	66811
its application	66811
spinal cord contusion and transection injuries	66830
J. Neurotrauma 18 , 187 -- 201 .	66878
J. Neurotrauma 18 , 187	66878
201	66901
Imaizumi , T. , Lankford , K.L. , Kocsis , J.D. , 2000 .	66906
Imaizumi , T. , Lankford , K.L. , Kocsis , J.D.	66906
2000	66950
Transplantation of olfactory ensheathing cells or Schwann cells	66956
Transplantation	66956
olfactory ensheathing cells or Schwann cells	66975
rapid and secure conduction	67029
the transected spinal cord	67064
Brain Res .	67092
Brain	67092
Res	67098
854 , 70 -- 78 .	67103
854	67103
70 -- 78	67108
Iwashita , Y. , Crang , A.J. , Blakemore , W.F. , 2000 .	67115
Iwashita , Y. , Crang , A.J. , Blakemore , W.F.	67115
2000	67159
Redistribution of bisbenzimide Hoechst 33342 from transplanted cells to host cells .	67165
Redistribution	67165
bisbenzimide Hoechst 33342 from transplanted cells to host cells	67183
bisbenzimide	67183
Hoechst 33342	67196
transplanted cells to host cells	67215
transplanted cells	67215
host cells	67237
NeuroReport 11 , 1013 -- 1016 .	67249
NeuroReport 11 , 1013	67249
1016	67270
Joosten , E.A. , 1997 .	67276
Joosten , E.A.	67276
1997	67291
Corticospinal tract regrowth .	67297
Corticospinal tract	67297
regrowth	67317
Prog .	67327
Neurobiol	67333
53 , 1 -- 25 .	67344
53	67344
1 -- 25	67348
Joosten , E.A. , Gribnau , A.A. , 1989 .	67354
Joosten , E.A. , Gribnau , A.A.	67354
1989	67384
Astrocytes and guidance of outgrowing corticospinal tract axons in the rat .	67390
Astrocytes and guidance	67390
corticospinal tract axons	67428
the rat	67457
An immunocytochemical study using anti-vimentin and anti-glial fibrillary acidic protein .	67466
An immunocytochemical study	67466
anti-vimentin and anti-glial fibrillary acidic protein	67500
anti-vimentin	67500
anti-glial fibrillary acidic protein	67518
Neuroscience 31 , 439 -- 452 .	67556
Neuroscience 31 , 439	67556
452	67577
Joosten , E.A. , Veldhuis , W.B. , Hamers , F.P. , 2004 .	67582
Joosten , E.A. , Veldhuis , W.B. , Hamers , F.P.	67582
2004	67626
Collagen containing neonatal astrocytes	67632
Collagen	67632
neonatal astrocytes	67652
regrowth of injured fibers	67683
regrowth	67683
injured fibers	67695
modest locomotor recovery	67723
spinal cord injury	67755
J. Neurosci .	67775
Res	67788
77 , 127 -- 142 .	67793
77	67793
127 -- 142	67797
Koopmans , G.C. , Deumens , R. , Honig , W.M. , Hamers , F.P. , Steinbusch , H.W. , Joosten , E.A. , 2005 .	67806
Koopmans , G.C. , Deumens , R. , Honig , W.M. , Hamers , F.P. , Steinbusch , H.W. , Joosten , E.A.	67806
2005	67895
The assessment of locomotor function in spinal cord injured rats : the importance of objective analysis of coordination .	67901
The assessment of locomotor function in spinal cord injured rats	67901
The assessment	67901
locomotor function in spinal cord injured rats	67919
locomotor function	67919
spinal cord injured rats	67941
spinal cord	67941
rats	67961
the importance of objective analysis of coordination	67967
the importance	67967
objective analysis of coordination	67985
objective analysis	67985
coordination	68007
J. Neurotrauma 22 , 214 -- 225 .	68021
J. Neurotrauma 22 , 214	68021
225	68044
Li , Y. , Field , P.M. , Raisman , G. , 1997 .	68049
Li , Y. , Field , P.M. , Raisman , G.	68049
1997	68083
Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells .	68089
Repair	68089
adult rat corticospinal tract	68099
transplants of olfactory ensheathing cells	68132
transplants	68132
olfactory ensheathing cells	68147
Science 277 , 2000 -- 2002 .	68176
Science 277 , 2000	68176
2002	68194
Li , Y. , Field , P.M. , Raisman , G. , 1998 .	68200
Li , Y. , Field , P.M. , Raisman , G.	68200
1998	68234
Regeneration of adult rat corticospinal axons	68240
Regeneration	68240
adult rat corticospinal axons	68256
adult rat	68256
corticospinal axons	68266
transplanted olfactory ensheathing cells	68297
transplanted olfactory ensheathing	68297
cells	68332
J. Neurosci .	68339
18 , 10514 -- 10524 .	68352
18	68352
10514 -- 10524	68356
Li , Y. , Decherchi , P. , Raisman , G. , 2003 .	68369
Li , Y. , Decherchi , P. , Raisman , G.	68369
2003	68405
Transplantation of olfactory ensheathing cells into spinal cord lesions	68411
Transplantation	68411
olfactory ensheathing cells into spinal cord lesions	68430
olfactory ensheathing cells	68430
spinal cord lesions	68463
breathing and climbing	68492
J. Neurosci .	68516
23 , 727 -- 731 .	68529
23	68529
727 -- 731	68533
Li , Y. , Field , P.M. , Raisman , G. , 2005 .	68542
Li , Y. , Field , P.M. , Raisman , G.	68542
2005	68576
Olfactory ensheathing cells and olfactory nerve fibroblasts	68582
Olfactory ensheathing cells	68582
olfactory nerve fibroblasts	68614
continuous open channels for regrowth of olfactory nerve fibres	68651
continuous open channels	68651
regrowth of olfactory nerve fibres	68680
regrowth	68680
olfactory nerve fibres	68692
Glia 52 , 245 -- 251 .	68716
Glia 52	68716
245 -- 251	68725
Lu , J. , Feron , F. , Ho , S.M. , Mackay-Sim , A. , Waite , P.M. , 2001 .	68734
Lu , J. , Feron , F. , Ho , S.M. , Mackay-Sim	68734
A.	68775
Waite	68778
P.M.	68785
2001	68791
Transplantation of nasal olfactory tissue	68797
Transplantation	68797
nasal olfactory tissue	68816
partial recovery in paraplegic adult rats	68848
partial recovery	68848
paraplegic adult rats	68868
Brain Res .	68891
Brain	68891
Res	68897
889 , 344 -- 357 .	68902
889	68902
344 -- 357	68907
Mainil-Varlet , P. , Curtis , R. , Gogolewski , S. , 1997 .	68916
Mainil-Varlet , P. , Curtis , R. , Gogolewski , S.	68916
1997	68963
Effect of in vivo and in vitro degradation on molecular and mechanical properties of various lowmolecular - weight polylactides .	68969
Effect of in vivo and in vitro degradation on molecular and mechanical properties of various lowmolecular	68969
Effect	68969
in vivo and in vitro degradation	68979
vivo	68982
molecular and mechanical properties of various lowmolecular	69015
molecular and mechanical properties	69015
various lowmolecular	69054
weight polylactides	69076
J. Biomed .	69097
Mater .	69108
Res	69115
36 , 360 -- 380 .	69120
36	69120
360 -- 380	69124
Maquet , V. , Martin , D. , Scholtes , F. , Franzen , R. , Schoenen , J. , Moonen , G. , Jerme , R. , 2001 .	69133
Maquet , V. , Martin , D. , Scholtes , F. , Franzen , R. , Schoenen , J. , Moonen , G. , Jerme , R.	69133
2001	69221
Poly -LRB- D,L-lactide -RRB- foams modified by poly -LRB- ethylene oxide -RRB- - block-poly -LRB- D,L-lactide -RRB- copolymers and a-FGF : in vitro and in vivo evaluation for spinal cord regeneration .	69227
Poly -LRB- D,L-lactide -RRB- foams modified by poly -LRB- ethylene oxide -RRB-	69227
Poly -LRB- D,L-lactide -RRB- foams modified by poly	69227
Poly	69227
D,L-lactide	69232
foams	69245
poly	69263
ethylene oxide	69268
block-poly -LRB- D,L-lactide -RRB- copolymers and a-FGF	69285
block-poly	69285
D,L-lactide	69296
copolymers and a-FGF	69309
in vitro and in vivo evaluation for spinal cord regeneration	69331
in vitro and in vivo evaluation	69331
vivo	69347
spinal cord regeneration	69367
Biomaterials 22 , 1137 -- 1146 .	69393
Biomaterials 22	69393
1137 -- 1146	69410
Nash , H.H. , Borke , R.C. , Anders , J.J. , 2002 .	69421
Nash , H.H. , Borke , R.C. , Anders , J.J.	69421
2002	69460
Ensheathing cells and methylprednisolone	69466
Ensheathing cells	69466
methylprednisolone	69488
axonal regeneration and functional recovery in the lesioned adult rat spinal cord	69515
axonal regeneration and functional recovery	69515
the lesioned adult rat spinal cord	69562
J. Neurosci .	69598
22 , 7111 -- 7120 .	69611
22	69611
7111 -- 7120	69615
Oudega , M. , Vargas , C.G. , Weber , A.B. , Kleitman , N. , Bunge , M.B. , 1999 .	69626
Oudega , M. , Vargas , C.G. , Weber , A.B. , Kleitman , N. , Bunge , M.B.	69626
1999	69692
Long-term effects of methylprednisolone following transection of adult rat spinal cord .	69698
Long-term effects	69698
methylprednisolone following transection of adult rat spinal cord	69719
methylprednisolone following transection	69719
adult rat spinal cord	69763
Eur	69786
J. Neurosci .	69791
11 , 2453 -- 2464 .	69804
11	69804
2453 -- 2464	69808
Pallini , R. , Fernandez , E. , Sbriccoli , A. , 1988 .	69819
Pallini , R. , Fernandez , E. , Sbriccoli ,	69819
A. , 1988	69858
A.	69858
1988	69862
Retrograde degeneration of corticospinal axons following transection of the spinal cord in rats .	69868
Retrograde degeneration	69868
corticospinal axons following transection of the spinal cord in rats	69895
corticospinal axons	69895
transection of the spinal cord in rats	69925
transection	69925
the spinal cord in rats	69940
the spinal cord	69940
rats	69959
A quantitative study with anterogradely	69965
A quantitative study	69965
anterogradely	69991
horseradish peroxidase	70017
J. Neurosurg .	70041
68 , 124 -- 128 .	70055
68	70055
124 -- 128	70059
Pasterkamp , R.J. , Giger , R.J. , Ruitenberg , M.J. , Holtmaat , A.J. , De Wit , J. , De Winter , F. , Verhaagen , J. , 1999 .	70068
Pasterkamp , R.J. , Giger , R.J. , Ruitenberg , M.J. , Holtmaat , A.J. , De Wit , J. , De Winter , F. , Verhaagen , J.	70068
1999	70175
Expression of the gene encoding the chemorepellent semaphorin III	70181
Expression	70181
the gene encoding the chemorepellent semaphorin III	70195
the gene	70195
the chemorepellent semaphorin III	70213
the fibroblast component of neural scar tissue formed following injuries of adult but not neonatal CNS	70261
the fibroblast component	70261
neural scar tissue formed following injuries of adult but not neonatal CNS	70289
neural scar tissue	70289
injuries of adult but not neonatal CNS	70325
injuries	70325
adult but not neonatal CNS	70337
adult	70337
neonatal CNS	70351
Mol	70365
Cell .	70370
Neurosci	70376
13 , 143 -- 166 .	70386
13	70386
143 -- 166	70390
Perez-Bouza , A. , Wigley , C.B. , Nacimiento , W. , Noth , J. , Brook , G.A. , 1998 .	70399
Perez-Bouza	70399
A.	70412
Wigley , C.B. , Nacimiento , W. , Noth , J. , Brook , G.A.	70416
1998	70469
Spontaneous orientation of transplanted olfactory glia	70475
Spontaneous orientation	70475
transplanted olfactory glia	70502
axonal regeneration	70541
NeuroReport 9 , 2971 -- 2975 .	70562
NeuroReport 9 , 2971	70562
2975	70582
Plant , G.W. , Christensen , C.L. , Oudega , M. , Bunge , M.B. , 2003 .	70588
Plant	70588
G.W. , Christensen , C.L. , Oudega , M. , Bunge , M.B. , 2003	70595
G.W. , Christensen , C.L. , Oudega , M. , Bunge , M.B. ,	70595
2003	70645
Delayed transplantation of olfactory ensheathing glia	70651
Delayed transplantation	70651
olfactory ensheathing glia	70678
sparing/regeneration of supraspinal axons in the contused adult rat spinal cord	70714
sparing/regeneration	70714
supraspinal axons in the contused adult rat spinal cord	70738
supraspinal axons	70738
the contused adult rat spinal cord	70759
J. Neurotrauma 20 , 1 -- 16 .	70795
J. Neurotrauma 20 , 1	70795
16	70816
Raisman , G. , 2001 .	70820
Raisman , G.	70820
2001	70833
Olfactory ensheathing cells -- Another miracle cure for spinal cord injury ?	70839
Olfactory ensheathing cells	70839
Another miracle cure for spinal cord injury	70867
Another miracle cure	70867
spinal cord injury	70892
Nat .	70912
Rev. , Neurosci .	70917
Rev.	70917
Neurosci	70923
2 , 369 -- 375 .	70933
2	70933
369 -- 375	70936
Ramon-Cueto , A. , Avila , J. , 1998 .	70945
Ramon-Cueto	70945
A.	70958
Avila	70962
J.	70969
1998	70973
Olfactory ensheathing glia : properties and function .	70979
Olfactory ensheathing glia	70979
properties and function	71007
properties	71007
function	71022
Brain Res .	71032
Brain	71032
Res	71038
Bull .	71043
46 , 175 -- 187 .	71049
46	71049
175 -- 187	71053
Ramon-Cueto , A. , Nieto-Sampedro , M. , 1992 .	71062
Ramon-Cueto , A. , Nieto-Sampedro , M.	71062
1992	71099
Glial cells from adult rat olfactory bulb : immunocytochemical properties of pure cultures of ensheathing cells .	71105
Glial cells from adult rat olfactory bulb	71105
Glial cells	71105
adult rat olfactory bulb	71122
immunocytochemical properties of pure cultures of ensheathing cells	71148
immunocytochemical properties	71148
pure cultures of ensheathing cells	71181
pure cultures	71181
ensheathing cells	71198
Neuroscience 47 , 213 -- 220 .	71217
Neuroscience 47 , 213	71217
220	71238
Ramon-Cueto , A. , Cordero , M.I. , Santos-Benito , F.F. , Avila , J. , 2000 .	71243
Ramon-Cueto	71243
A.	71256
Cordero , M.I. , Santos-Benito , F.F. , Avila , J.	71260
2000	71307
Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia .	71313
Functional recovery	71313
paraplegic rats and motor axon regeneration	71336
paraplegic rats	71336
motor axon regeneration	71356
their spinal cords	71383
olfactory ensheathing glia	71405
Neuron 25 , 425 -- 435 .	71433
Neuron 25	71433
425 -- 435	71444
Richardson , P.M. , Issa , V.M. , Aguayo , A.J. , 1984 .	71453
Richardson , P.M. , Issa , V.M. , Aguayo , A.J.	71453
1984	71497
Regeneration of long spinal axons in the rat .	71503
Regeneration	71503
long spinal axons	71519
the rat	71540
J. Neurocytol .	71549
13 , 165 -- 182 .	71564
13	71564
165 -- 182	71568
Sasaki , M. , Lankford , K.L. , Zemedkun , M. , Kocsis , J.D. , 2004 .	71577
Sasaki , M. , Lankford , K.L. , Zemedkun , M. , Kocsis , J.D.	71577
2004	71633
olfactory ensheathing cells	71650
the transected dorsal funiculus bridge the lesion and form myelin	71696
the	71696
dorsal funiculus bridge the lesion and form	71711
dorsal funiculus bridge	71711
the lesion and form	71735
J. Neurosci .	71763
24 , 8485 -- 8493 .	71776
24	71776
8485 -- 8493	71780
Schnell , L. , Schwab , M.E. , 1990 .	71791
Schnell , L. , Schwab , M.E.	71791
1990	71818
Axonal regeneration in the rat spinal cord	71824
Axonal regeneration	71824
the rat spinal cord	71847
an antibody against myelin-associated neurite growth inhibitors	71879
an antibody	71879
myelin-associated neurite growth inhibitors	71899
Nature 343 , 269 -- 272 .	71944
Nature 343 , 269	71944
272	71960
Schnell , L. , Schwab , M.E. , 1993 .	71965
Schnell , L. , Schwab , M.E.	71965
1993	71992
Sprouting and regeneration of lesioned corticospinal tract fibres in the adult rat spinal cord .	71998
Sprouting and regeneration	71998
lesioned corticospinal tract fibres in the adult rat spinal cord	72028
lesioned corticospinal tract fibres	72028
the adult rat spinal cord	72067
Eur	72094
J. Neurosci .	72099
5 , 1156 -- 1171 .	72112
5	72112
1156 -- 1171	72115
Schnell , L. , Schneider , R. , Kolbeck , R. , Barde , Y.A. , Schwab , M.E. , 1994 .	72126
Schnell , L. , Schneider , R. , Kolbeck , R. , Barde , Y.A. , Schwab , M.E.	72126
1994	72194
Neurotrophin-3	72200
corticospinal tract	72237
development	72264
adult spinal cord lesion	72286
Nature 367 , 170 -- 173 .	72312
Nature 367 , 170	72312
173	72328
Starkey , M.L. , Hamers , F.F. , Doherty , P. , McMahon , S.B. , Bradbury , E.J. , 2004 .	72333
Starkey , M.L. , Hamers , F.F. , Doherty , P. , McMahon , S.B. , Bradbury , E.J.	72333
2004	72406
behavioural function following unilateral lesion of the corticospinal tract in adult mice	72422
behavioural function	72422
unilateral lesion of the corticospinal tract in adult mice	72453
unilateral lesion	72453
the corticospinal tract in adult mice	72474
the corticospinal tract	72474
adult mice	72501
Program No 43102004 Abstract Viewer/Itinerary Planner .	72513
Program	72513
No 43102004 Abstract Viewer/Itinerary Planner	72521
No 43102004	72521
Abstract Viewer/Itinerary Planner	72533
Society for Neuroscience , Washington , DC .	72568
Society	72568
Neuroscience , Washington , DC	72580
Neuroscience	72580
Washington , DC	72594
von Meyenburg , J. , Brosamle , C. , Metz , G.A. , Schwab , M.E. , 1998 .	72610
von Meyenburg , J. , Brosamle , C. , Metz , G.A. , Schwab , M.E.	72610
1998	72669
Regeneration and sprouting of chronically injured corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1 , which neutralizes myelinassociated neurite growth inhibitors .	72675
Regeneration and sprouting of chronically injured corticospinal tract fibers	72675
Regeneration and sprouting	72675
chronically injured corticospinal tract fibers	72705
adult rats promoted by NT-3 and the mAb IN-1 , which neutralizes myelinassociated neurite growth inhibitors	72755
adult rats	72755
NT-3 and the mAb IN-1	72778
NT-3	72778
the mAb IN-1	72787
myelinassociated neurite growth inhibitors	72819
Exp .	72863
Neurol	72868
154 , 583 -- 594 .	72876
154	72876
583 -- 594	72881
Wagner Jr. , F.C. , VanGilder , J.C. , Dohrmann , G.J. , 1978 .	72890
Wagner Jr. , F.C. , VanGilder , J.C. , Dohrmann , G.J.	72890
1978	72941
Pathological changes from acute to chronic in experimental spinal cord trauma .	72947
Pathological changes	72947
acute to chronic in experimental spinal cord trauma	72973
chronic in experimental spinal cord	72982
chronic	72982
experimental spinal cord	72993
J. Neurosurg .	73026
48 , 92 -- 98 .	73040
48	73040
92 -- 98	73044
Woodhouse , A. , Vincent , A.J. , Kozel , M.A. , Chung , R.S. , Waite , P.M. , Vickers , J.C. , West , A.K. , Chuah , M.I. , 2005 .	73051
Woodhouse	73051
A.	73062
Vincent , A.J. , Kozel , M.A. , Chung , R.S. , Waite , P.M. , Vickers , J.C. , West , A.K. , Chuah , M.I.	73066
2005	73160
Spinal cord tissue	73166
ensheathing cell proliferation and apoptosis	73193
ensheathing cell proliferation	73193
apoptosis	73228
NeuroReport 16 , 737 -- 740 .	73239
NeuroReport 16 , 737	73239
740	73259
